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Abstract 
Introduction: This thesis aims to advance magnetic resonance imaging (MRI) for imaging 
cellular therapeutics.  Traditional, proton-based, MRI provides detailed anatomical images, 
particularly of soft tissue. However, in order to obtain information at a cellular level 
specialized imaging agents are required to detect the cells of interest. Perfluorocarbons 
containing non-radioactive fluorine-19 (19F) are both biologically safe and MR sensitive.    
Methods: Pre-clinical 19F-MRI was implemented on a Varian 9.4T MRI scanner, using a 
dual 19F/1H-tuned birdcage volume coil. Mesenchymal stromal cells (MSC) were pre-labeled 
with a commercial, FDA approved 19F-perfluorocarbon emulsion, then implanted 
intramuscularly into the mouse hindlimb. To track the inflammation resulting from 
transplantation, a dual-agent cellular MRI technique was developed.  This technique utilizes 
19F to track MSC and superparamagnetic iron oxide nanoparticles (SPIO) to image 
macrophages, through signal quenching. A clinical imaging protocol was developed to 
translate 19F-MRI to a 3T GE MR750 scanner with a dual 19F/1H-tuned surface coil. 
Peripheral blood mononuclear cells (PBMC) were labeled with a FDA-approved 19F-agent 
and injected into a ham shank phantom for protocol optimization.   Results:  The balanced 
steady-state free precession pulse sequence was chosen for all studies due to the high signal-
to-noise per unit time.  Image acquisition was optimized for 19F detection sensitivity, 
accuracy of quantification, and compatibility with isoflurane. In vivo quantification of MSC 
on the day of implantation was in strong agreement with the expected number of cells. The 
change in 19F-signal was quantified over time and compared between two murine 
transplantation models. When iron oxide was administered i.v., the migration of immune 
cells could be tracked to the injection site.  The presence of SPIO decreased both the 1H and 
19F signal, indicating that transplant rejection was occurring. On a clinical system, as few as 
4x106 PBMC could be imaged following both surface and subcutaneous injection. The 
minimum number of detectable cells was strongly influenced by intracellular 19F uptake.  
Conclusions: 19F-MRI is a promising tool for imaging cellular therapeutics.  By pre-labeling 
cells of interest, they can be localized and the change in signal can be quantified over time. 
The technique shows promise for both pre-clinical and clinical applications.   
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centrifuging 1x106, 5x106 and 10x106 Cell Sense-labeled PBMC and overlaying with 1% 
agarose in an eppendorf tube (C). PBMC phantoms were placed on a saline bag and scanned 
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Chapter 1  
1 Introduction* 
This thesis develops and advances magnetic resonance imaging (MRI) techniques for 
non-invasive, in vivo tracking of cellular therapeutics.  Research was performed with 
imaging phantoms and animal models.  This introductory chapter discusses cell therapy, 
cellular imaging techniques, and cellular MRI to provide background and motivation for 
the research presented in this thesis. 
1.1 Cellular Therapy 
Cell therapy involves the administration of healthy cells into a patient in order to treat a 
disease or condition.  Therapeutic cells from the patient can be specialized and expanded 
in vitro, then re-administered to the most favourable location in the patient. Pre-clinical 
experiments have shown that cellular therapy has the potential to revolutionize numerous 
fields within modern medicine; with applications ranging from regenerative medicine to 
immunotherapy.  
1.1.1 Regenerative Medicine 
Stem cell transplants are of particular interest for treating a variety of chronic disorders.  
Defined by the cell potency, “true” stem cells are pluripotent allowing for differentiation 
into any cell type. Multipotent stem cells, also known as progenitor cells, have the 
potential to differentiate into multiple cell types, but are limited compared to pluripotent 
cells. Mesenchymal stem cells (MSC) were first defined in 1991 by A.I. Caplan. to 
denote the 
___________________ 
*This chapter contains sections which have been previously published. Section 1.3.1, and 
1.4 contain exerts from: Fox MS, Gaudet JM, and PJ Foster (2015) “Fluorine-19 MRI 
contrast agents for cell tracking and lung imaging,” Magnetic Resonance Insights 
8(S1):1-15. Copyright is held by the authors. Section 1.3, 1.3.2, and 1.3.3 contains exerts 
from: Makela AV & Murrell DH, Parkins KM, Kara J, Gaudet JM and PJ Foster (2016) 
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“Cellular Imaging with MRI,” Topics in Magnetic Resonance Imaging 25(5): 177-186. 
Sections are reproduced with permission (see Appendix A). 
 
stromal progenitor and presumed stem cells for the skeletal tissues of bone, cartilage, 
muscle and fat.1 First derived from bone marrow, MSCs are one of the most investigated 
stem-like cells in clinical research. With applications in generating cardiac muscle,2,3 
stroke recovery,4,5 and osteoarthritis repair;6 MSCs have the additional advantage of 
being present in adult tissue. In addition to directly replacing damaged tissues, stem cells 
have been shown to exert a local therapeutic effect through the release of trophic 
factors.2,7,8 Studies have shown that under the right conditions MSCs can be induced to 
pluripotency. However, recent work has shown that individual MSCs in culture are often 
already pre-dispositioned to certain lineages, disputing the claim of true multipotency.7,9 
This has led to extensive debate on “how potent” an individual cell must remain to be 
considered a stem cell.7,9,10 Numerous groups have advocated for new definitions of 
MSCs, differentiating multipotent stromal cells from bone marrow derived mesenchymal 
stem cells.9,11,12  For simplicity, the term MSC as used in the remainder of this thesis 
refers to the encompassing broad MSC definition, without attempting to differentiate 
based upon the potency of the cells in culture. 
Ultimately, the restorative effects of regenerative medicine relies on the arrival and 
survival of the cells at the targeted destination. Stem cells can be administered either 
systemically or at the therapeutic site.7  In either case, the cells must adapt to the local 
environment following expansion and specification in culture. Studies have shown that 
the majority of stem cells die in the days following transplantation.13–17 This may occur 
from a number of factors, such as: shear stresses encountered with needle delivery or 
insufficient access to nutrients.  In either event, pro-inflammatory cytokines are released 
by dying stem cells, which in sufficient quantities is capable of trigging an influx of 
immune cells to the site of transplant.18,19   
Transplant rejection is further mediated by differences in the genetic background of the 
stem cells and host. This can occur as a rapid acute response from the recipient’s immune 
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system towards the major histocompatibility complex (MHC) of the donated cells,18,19 or 
a long-term chronic rejection involving loss of vascularity.19 Alternatively, in the case of 
tissue transplants, donor immune cells present within the transplant may attack the host 
tissue; a process known as graft-versus-host disease (GVHD). For human cellular 
transplants, ideally stem cells are collected from the individual patient themselves, 
preventing adaptive immune rejection and GVHD, producing an autologous transplant.  
However, depending on the disease/condition and previous therapeutic treatments, these 
autologous cells may not be suitable for administration.  Isografts are a near-ideal 
alternative with donor cells produced by a genetically identical background, such as an 
identical twin. Clinically, allograft transplantations are the most common, involving non-
genetically identical donors. In these cases, immunosuppressive drugs are commonly 
required to prevent transplant rejection.  Recent work has suggested that MSCs may 
display immune privileged properties, potentially allowing for unassisted allogeneic 
donation.7,12,20 However the degree of immune suppression has been contested with many 
reports suggesting it is insufficient to prevent allograft rejection.12,16  
These models can be tested pre-clinically; with isografts produced by in-bred murine 
strains and allografts using cells between murine strains. In addition, xenografts can be 
investigated with donated cells from a different species as the host. This often results in 
hyper-acute rejection of the transplants,21 although stable xenografts can be produced 
with severely immune-compromised mice transplanted with human stem cells. 
1.1.2 Immunotherapy 
In the field of cancer immunotherapy, the patient’s immune system is primed to target the 
tumour. This can be accomplished by introducing antigen-presenting cells (APCs) which 
have been exposed to tumour antigen in vitro prior to administration. Once treatment has 
been delivered to the patient, the APCs must migrate to a secondary lymphoid organ in 
order to elicit an immune response. Here APCs interact with other cells of the adaptive 
immune system, such as T-cells, which ultimately proceed to target the tumour.22–24  
Unlike traditional prophylactic vaccines, these treatments are meant to be therapeutic 
providing alternative treatment options.   
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For many years, dendritic cells (DCs) have been investigated as the ideal APC for 
application in immunotherapy.  In vivo, DCs play a pivotal role in initiating the immune 
response to foreign antigens.  Capable of being derived from bone marrow or blood 
monocytes; DCs are characterized as highly MHC II expressing, with the absence of 
lineage markers, such as: CD14 (monocytes), CD19 (B-cells), and CD68 
(macrophages).25,26  Since the first DC clinical trial was reported in 1996 for B-cell 
lymohoma,27 many patients have undergone vaccination trials for a range of cancers. 
Unfortunately, clinical success of DC-therapy has been limited with the majority of trials 
failing to show significant survivorship benefit.22,23,28,29 It is clear that additional research 
is necessary to improve DC migratory efficiency and ensure immune tolerance is avoided 
to improve clinical outcomes.28 
On April 29, 2010, Sipuleucel-T, a cellular vaccine treatment was approved and licenced 
by the US FDA for metastatic castrate-resistant prostate cancer (mCRPC). Although 
localized prostate cancer has a good prognosis, there are currently few treatment options 
following systemic spread.  In multiple Phase III clinical trials, Sipuleucel-T has shown a 
statistically significant survivor benefit over placebo controlled groups.24,30  Treatment 
involves loading autologous peripheral blood mononuclear cells (PBMC) with an antigen 
construct containing prostatic acid phosphatase (PAP) and granuocyte macrophage 
colony-stimulating factor (GM-CSF).  The PBMC fraction consists of a heterogeneous 
mixture of cells, containing professional APCs, such as: DCs, monocytes, and B-cells; 
along with activated: T- and NK cells. Following in vitro antigen loading of the PBMC, 
the cells are administered intravenously back into the patient.31  While cancer 
immunotherapy has only shown modest overall survival benefits in the clinic, 
progression-free survival was not significantly improved.30,32 Coupled with the high cost 
of treatment innovative approaches, such as those presented within this thesis, are 
necessary to advance the clinical application of cancer immunotherapy.  
1.2 Magnetic Resonance Imaging 
The following sections are meant to provide a brief overview of the fundamental 
processes involved with generating an MR image. Additional information can be found in 
several textbooks, such as: “Magnetic Resonance Imaging: Physical Principles and 
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Sequence Design, 2nd ed.” by Robert Brown et al.33 and “From Picture to Proton” by 
McRobbie et al.34 
1.2.1 Nuclear Magnetic Resonance 
At the single voxel level, signal in MRI is derived from the dissipation of energy from 
spinning nuclei within a magnetic field.  All nuclei have a characteristic spin (I) value; 
however only those with non-zero spins (I=1/2, 1, 3/2, …) produce a nuclear magnetic 
resonance signal.  In MRI, most nuclei of interest are spin ½.  When a collection of spins 
are placed within an external magnetic field (B0), these spins either align with or against 
the applied field.  Signal in MRI is governed by the small excess proportion of these 
spins in the lowest energy state; or those in alignment with B0.  The energy difference 
between the two states is dependent on the strength of B0, as shown in Equation 1. 
 ∆" = 	 %&'(   (eq.1) 
Where µ is the nuclei’s magnetic moment (discussed further in Table 1). As the 
difference in energy level increases, a higher proportion of spins align with B0.  At 
thermal equilibrium, the ratio of spins in each population can be described with the 
Boltzmann distribution (Eq. 2). Here, N+ and N- represent the number of spins in 
alignment with or against B0 respectively, k is the Boltzmann constant, and T is the 
temperature of the system. For this reason, imaging at higher field strengths (7T, 9.4T, 
11.7T) improves signal compared to clinical magnets (1.5T, 3T).   
 )* )+ = 	,-∆./0  (eq.2) 
In addition to spin state, nuclei also present a characteristic precession about the main 
magnetic field. Governed by the nuclei’s gyromagnetic ratio (g) and B0, the Larmor 
frequency is given by Equation 3.  
 12 = 	342 (eq.3) 
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Table 1: Properties of relevant nuclei 
Element 
Gyromagnetic 
Ratio (MHz/T) 
Natural 
Abundance (%) 
Magnetic moment  
(5/5N) Nuclear Spin 
1H 42.57 99.98 2.793 ½ 
19F 40.08 100 2.629 ½ 
Energy can be provided to excite the nuclei by applying a radiofrequency (RF) pulse at 
the nuclei’s Larmour frequency.  Following excitation, the net magnetization (M) returns 
to the lowest energy state through the longitudinal (T1) and transverse (T2) relaxation 
time constants. T1 relaxation involves the growth of magnetization (Fig 1A), along the 
direction of the B0 field, defined as the z-axis. This occurs through the transfer of energy 
from the excited nuclei to the lattice.  T2 relaxation governs the exponential decay of 
magnetization (Fig 1B) within the xy-plane through transfer of energy between spins 
resulting in loss of phase coherence. The observed transverse relaxation rate (1/T2*) is 
accelerated due to reversible dephasing because of: off resonance effects, molecular 
mechanisms, and magnetic field inhomogeneities.   
 
Figure 1: Graphs of Longitudinal and Transverse Relaxation rates.  In both cases 
the y-axis is normalized to M0, the magnetization of the sample induced by the main 
magnetic field.  
  
7 
1.2.2 Generating an Image 
In MRI a magnetic field gradient along each Cartesian axis (x,y,z) is utilized to provide 
spatial localization of voxels. These magnetic gradients are many orders of magnitude 
smaller than the main magnetic field and are highly controlled. The application of a 
gradient influences the precession frequency of the nuclei across the gradient, resulting in 
a distribution of phases associated with the spatial location. Spatial information is 
obtained by assigning a unique initial phase and frequency to each location. This 
achieved by manipulating the duration and magnitude of these gradients across the field 
of view.  
The timed RF excitation and magnetic field manipulations are defined in the MR pulse 
sequence.  There are two categories of sequences, characterized by the method used to 
generate transverse magnetization coherence.  In a standard spin echo (SE) sequence, 
spins are first excited by a 90° RF pulse.  Magnetization is refocused (known as an echo) 
some time later by applying a second RF pulse, which reverses the direction of the spins. 
This reversal causes the spins to rephase and regain spin coherence at the echo time (TE).  
Due to the second RF pulse, SE sequences refocus all reversible signal and have the 
advantage of obtaining optimal signal per excitation, governed by T2.   
The second type of sequence forms an echo through inverting the applied magnetic field 
gradient. For gradient echo (GE) sequences, an initial RF pulse is again used to excite the 
spins, although the flip angle is generally <90°. After excitation, the frequency encode 
gradients are applied to enhance dephasing, then reversed in amplitude to form an echo at 
TE. However, the resulting echo does not correct for field inhomogeneities, resulting in 
the T2* reductions to signal.  Despite obtaining lower signal per excitation, this is offset 
by the capability to perform lower repetition times (TR) between excitations; which 
allows for more signal averaging within the same time period. 
In either case, the formation of an echo induces a current in the receive coil which is 
translated into a digital signal and stored in an array matrix known as k-space. Data in k-
space represent spatial frequencies, with each individual point containing frequency and 
phase information on every voxel in the corresponding image. The center of k-space 
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contains information on low frequencies, such as crude contrast and shapes; while high 
frequency information is found in the periphery of k-space, providing the boundaries and 
details. From here the data can be extracted from k-space and an MR image formed using 
the Fourier transform.  This acts to separate the signal into a sum of sine waves with 
varying frequency, phase, and amplitude.   
The signal intensities of an individual image voxel are governed by three factors: the spin 
density, T1, and T2 values of the material being imaged.  The spin density governs the 
maximum potential magnetization (M0) providing the upper limit on the signal available 
to be detected.  Image contrast is also influenced by the choice of pulse sequence and can 
be manipulated by adjusting the TR and TE of the sequence.  For example, imaging with 
a long TE allows material with a short T2 to relax reducing the observed signal. 
Meanwhile, material with a longer T2 would appear brighter as more spins are rephased 
to form the echo. The manipulating the TR has a similar effect on the images by varying 
the magnetization excited into the xy plane.   
1.2.3 Balanced Steady-State Free Precession 
Balanced steady-state free precession (bSSFP) is an advanced GE pulse sequence, and is 
also known by the vender specific names FIESTA, TrueFISP, and Balanced FFE. Unlike 
with conventional sequences, magnetization is not allowed to completely return to Mo 
prior to re-excitation.  This generates a transverse and longitudinal magnetization steady-
state after successive excitations.  In addition, all gradient waveforms are also balanced to 
a net value of zero in each TR, as shown below in Figure 2.   
Due to the magnetization steady-state, contrast is dependent on the ratio between T2/T1.  
The optimal flip angle is given by Equation 4, and results in the magnetization amplitude 
given by Equation 5.35 
 cos 9 = :; :<+=:; :<*= (eq.4) 
 >?? = =@>2 A@ A= (eq.5) 
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Figure 2: Balanced steady-state free precession pulse sequence diagram. The time to 
form an echo (TE) is commonly set to ½ the repetition time (TR). In a single 
sequence repetition all gradient magnitudes are balanced to produce a net of 0. 
Figure adapted from “Picture to Proton”34  
bSSFP has the advantage of generating high signal-per-unit time images. This is 
accomplished by keeping TR extremely low (TR<<T1, often <10ms), which allows for 
high signal averaging. However, this has the disadvantage of requiring strong gradient 
slew rates and increased tissue heating, measured through specific absorption rate 
(SAR).35  
The pulse sequence displays a characteristic banding artifact. This occurs since the 
transverse magnetization approaches zero at multiples of 2p.  This can be offset by a 
technique known as phase cycling, which varies the location of the dark bands allowing 
for them to be removed through signal averaging.  
The high signal advantages and unique contrast generated by bSSFP have been utilized 
for real-time cardiac imaging,35 angiography,35 oncology,36 and cellular MRI.37,38 The 
lack of T2* dependence on signal is particularly useful for controlling the size of the 
blooming artifact produced by superparamagnetic iron oxide (SPIO) nanoparticles.    
  
10 
1.2.4 Iron Oxide-Contrast Agents 
In MRI, regions of interest (ROIs) can be emphasized using paramagnetic and 
superparamagnetic agents which influence the image contrast.  Localized positive 
enhancements to the signal can be achieved with gadolinium or manganese agents, while 
negative contrast can be generated with iron oxide agents.  When imaged with a MRI, 
SPIO particles result in a reduction in the local T1, T2, and T2*.  This is caused by 
disturbing the local magnetic susceptibility and is most pronounced in the immediate 
vicinity of the superparamagnetic material. With conventional sequences, the T2 and T2* 
reductions appear as a region of negative contrast on the image.  The size of this region is 
dependent on a number of factors, such as: the pulse sequence timing, method of echo 
formation, and field strength;39 with the largest effects visible in T2*-weighted images.33 
Positive image contrast is possible with certain advanced methods such as: ultrashort 
echo time (UTE) imaging, with the echo formed in less than the T2*;40 or through 
inversion recovery with on-resonance water suppression.41   
1.3 Imaging Cellular Therapeutics 
While pre-clinical experiments have shown that cellular therapy can be successful, 
despite decades of research, cellular therapy has been unable to meet clinical 
expectations.  One problem exists in that once these cells are re-administered to the 
patient it often takes months before diagnostic feedback is available. In this time, it is 
unknown if the cells are providing any therapeutic benefit to the patient. 
Cellular imaging aims to shed light on the in vivo fate of these therapeutic cells.  By 
directly and non-invasively imaging these cells, imaging provides a window through 
which we can confirm correct administration, observe migration, and evaluate 
longitudinal status of the cells. In the pre-clinical setting, imaging allows for more rapid 
treatment optimization in animal models, as data can be obtained throughout therapy 
instead of just at the endpoint.  In the clinic, imaging presents an avenue to evaluate the 
success of therapy at multiple time points, often before symptomatic indicators are 
available.  This provides the capability to verify both the success of delivery and evaluate 
treatment progression, providing the capability to intervene if necessary. 
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There are currently several established in vivo cell-tracking methods including: optical 
(fluorescence microscopy & bioluminescence imaging [BLI]), radioactive tracers 
(positron emission tomography [PET] & single-photon emission computed tomography 
[SPECT]), and MRI using heavy metal contrast agents (superparamagnetic iron oxide 
[SPIO] & paramagnetic gadolinium [Gd]).  Each of these modalities has their respective 
advantages and disadvantages.  For example, BLI signal is semi-quantitative and only 
produced by living cells, but is attenuated with tissue depth and requires non-native 
transfected cells.42,43  By comparison, PET is highly sensitive at all depths and is 
clinically translatable, but the ionizing radiation can be highly toxic to sensitive 
therapeutic cells.44  In addition to these methods, there are two recently developed 
technologies, magnetic particle imaging (MPI)45 and fluorine-MRI (19F-MRI).46 The 
relative differences between some of the more common techniques are compared in Table 
2.  The values presented are approximate guidelines of each technique; with values being 
highly dependent on imaging time, protocol and equipment. 
1.3.1 Cellular MRI 
In comparison to other cell imaging techniques, cellular MRI has the advantage of being 
clinically translatable without exposure to ionizing radiation. The anatomical images 
provide excellent spatial resolution and soft tissue contrast.  Most cellular MRI to date 
has been performed with SPIO. Cell tracking with iron oxide was first utilized by Bulte et 
al. and Yeh et al. in the early 1990s by internalizing iron oxide particles within cells and 
detecting the resulting negative signal contrast.47–49 The disruption of the local magnetic 
field can be used to determine the spatial localization of iron oxide.  In T2-weighted 
images this provides cell spatial localization near that of the proton image resolution. The 
resulting signal void occupies a much larger spatial region than the individual cells 
themselves preventing the need for magnification.  As previously discussed in Section 
1.2.4 and in Table 2, small quantities of label can have large detectable effects on the 
magnetization of the surrounding spins. This has led to extremely high detection 
sensitivity, with single cell detection possible under certain conditions.37,50  However, 
since detection of the agent relies on a change in image contrast, localization of the iron 
oxide is limited by low specificity.  Dark regions with low proton density, such as the 
  
12 
bone and lung, can appear similar to iron oxide signal void. In addition, in vivo 
quantification of iron containing cells is complex. The fractional signal loss produced by 
SPIO is only linear at very low concentrations of iron oxide, and quickly reaches a 
saturation point after which further signal loss does not occur.37 This makes it extremely 
difficult to quantify the amount of iron present within a signal void. Nevertheless, over 
the years SPIO have been used to track a vast range of cells, such as: immune cells,44,51–54 
stem cells,55–57 cancer cells,58–60 and pancreatic islets.61   
 
1.3.2 Labeling Therapeutic Cells for MRI 
Cells of interest must first be labeled with an imaging agent allowing for their specific 
detection.  These agents can be genetically engineered into the cells,68 administered to the 
cells in culture prior to administration,69 or injected intravenously to label native cells in 
situ.14  For imaging cellular therapeutics with MRI, the most common method employed 
to label cells is in vitro.  This provides the greatest control of label uptake, ensuring only 
the specific cells of interest are labeled.   
In general, there are three classes of iron oxide agents used in imaging: 1) ultra-small 
superparamagnetic iron oxide nanoparticles (USPIO) [5-50nm], 2) superparamagnetic 
iron oxide nanoparticles (SPIO) [50-150nm], and 3) micron-sized iron oxide particles 
(MPIO) [1µm].   A single MPIO particle contains >5pg/Fe, an amount equivalent to 1.5 
million SPIOs or 4.3 million USPIOs.70 The iron oxide core is often surrounded by a 
dextran coat to prevent aggregation and enhance biocompatability.71  Although there are 
no FDA approved iron oxide cell imaging agents, one agent is currently being 
investigated for off-label use.  Ferumoxytol is an I.V. administered USPIO-sized agent 
used to treat iron-deficiency. Many cell types are capable of taking up nanoparticle-sized 
agents without intervention, and these cells can be labeled to sufficient levels for imaging 
(>1pg/Fe per cell) by simple co-incubation. This is particularly important when 
considering clinical feasibility, since transfection agents are not required. Cells mediate 
  
Table 2: Comparison of common cell tracking techniques 
 
MRI - Iron oxide MRI - 19F PET - 18F62,63 SPECT - 111In64,65  MPI - Iron oxide45,66 BLI -luciferase42,67 
Sensitivity 
1-10 cells 
(0.01ng/voxel)37 
10,000 cells (300ng/voxel) 100-1000 cells 100-1000 cells 100 cells (5ng/voxel) 1000 cells 
Cellular loading >99% (1-10pg/cell)37 >99% (0.3-30pg19F/cell) 4-99% 4-25% (diluted) >99% (1-25pg/cell) >95% 
Resolution µm mm mm mm mm mm 
Bystander labeling Yes Yes Yes Yes Yes No 
Quantifiable Semi Yes Yes Yes Yes Semi 
Imaging Time Minutes Minutes Seconds Seconds Seconds Seconds 
Longitudinal potential Months Months Hours Days Months Months 
Total Imaging Cost $$$ $$$$ $$$ $$$ $ $ 
Clinical translatability Under evaluation Under evaluation Approved Approved No No 
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nanoparticle uptake through a variety of endocytosis pathways; including: phagocytosis, 
clathrin-, and caveolin-mediated endocytosis.41,72 The preferred method is dependent on 
cell type, as well as the size and surface coating of the agent.  Following internalization, 
the nanoparticles are contained within vesicles in the cytoplasm. Higher label-uptake is 
possible with phagocytic cells, which are capable of taking up additional label through 
phagocytosis.72 Following label internalization, it is also important to ensure that these 
agents do not induce functional or phenotypic changes in the cells that they label.  
Numerous studies have shown that labeling MSCs does not impact short- or long-term 
viability, proliferation, or differentiation into adipogenic or osteogenic lineages.56,73 
However, Rohani et al. demonstrated differences in activation and migration of DCs 
labeled with micron-sized iron oxide particles.51  
1.3.3 Imaging Inflammation 
Besides labeling cells in culture, phagocytic cells can also be labeled in situ following 
intravenous (i.v.) administration of an imaging agent.  This is particularly useful for 
tracking localized inflammation, through the large influx of immune cells.  In mice, the 
cellular imaging agent is administered through the tail vein with imaging performed 24 
hours later.  Most of the agent is cleared from the blood through the mononuclear 
phagocytic system, resulting in uptake by; Kupffer cells in the liver, monocytes in the 
bone marrow, and macrophages in the lymph nodes and spleen.  Applications have been 
shown in a variety of fields, such as: myocardial infarct,74,75 stroke,76  transplant 
rejection,13,14,53,77 tumour-associated macrophages,78,79 and spinal cord injury.80    
1.4 19F-MRI Cell Tracking 
The first 19F observations were attempted with NMR in 1942,81 followed by MRI in the 
1970s.82  Since then, 19F imaging agents have been used for a variety of purposes, such as 
to measure the intracellular partial pressure of oxygen83 and as a gastrointestinal contrast 
agent by proton displacement.84 Nuclear magnetic resonance signal from 19F has been 
used to investigate lung structure and drug pharmokinetics.  Unlike with iron oxide 
agents, nuclear magnetic resonance signal from the 19F atoms are directly detected and 
there is no disruption to the underlying proton image contrast.  Once the detection 
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threshold has been reached, the signal produced is linearly proportional to the number of 
19F atoms, allowing for quantification;85 details of which are expanded upon later in 
Chapter 2. A drawback of this direct detection is the relative insensitivity of the nuclear 
magnetic resonance signal.  As discussed in Section 1.2.1, signal in MRI is governed by 
the surplus of spins in alignment with the main magnetic field.  With standard MRI this is 
not a concern, due to the high abundance of 1H in biological tissue.  For 19F-MRI, a large 
number of additional 19F atoms must be introduced to the cell in order to produce enough 
NMR signal to be detectable.  This requires mM concentrations (~ 1015 19F atoms) per 
voxel for imaging.86  However, due to the near-absence of native 19F-atoms in biological 
tissue no background signal is observed, providing excellent imaging specificity.  
The first application of 19F-MRI for cell tracking was demonstrated in 2005 by Ahrens et 
al.46 In this study, immunotherapeutic DCs were tracked following subcutaneous 
injection to the draining popliteal lymph node.46 Cells were labeled in vitro by co-
incubation with an emulsified perflurocarbon (PFC), which was internalized through 
phagocytosis. Anatomical localization was achieved by overlaying the 19F image onto a 
traditional proton MR image. In the 11 years since this first study, the field has grown at 
an exponential rate,87 with significant advances in hardware,88–90 image acquisition,56,91,92 
and data processing.93,94 To date, most of this work has been performed at high-field 
strengths (>7 T), to improve sensitivity of 19F-MRI. Studies have demonstrated 19F can be 
added to cells in culture and used to track stem cells from hematopoietic,95 neuronal,96 
and mesenchymal progenitors;56 as well as a variety of immune cells, such as: DCs,46,97,98 
NK cells,99 T-cells,100 and macrophages.77 PFC uptake has been observed in both T- and 
B-cells, which have been historically difficult to label with SPIO-based agents.100  
Dendritic cells have been by far the most frequently imaged cell type with 19F-MRI.  
Besides the natural phagocytic ability allowing for high intracellular label uptake in the 
range of 1012 19F atoms/ cell; DC do not undergo mitotic cell division preventing the 
diffusion of label. Finally, the known migratory pathway to the draining lymph nodes 
provides the perfect translation model for assessing in vivo functionality with imaging.  
Building on previous work by Dr. Ahrens, in 2010 Helfer et al. introduced the first 
commercial 19F imaging agent by imaging the migration of DCs to the draining popliteal 
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lymph node.97 In this study, extensive work was performed to show that labeling did not 
negatively affect the expression of surface markers, DC maturation, and T-cell 
stimulatory function.97 In 2011, a German group led by Dr. Waiczies showed that the 
labeling efficiency of DCs increased with the PFC particle size, up to a maximum of 
560nm diameter.101 Interestingly, their work showed improved T-cell activation 
following 19F-loading of DCs;101 suggesting heavy intracellular 19F-uptake may act to 
induce DC maturation processes.  With these promising results, the clinical feasibility of 
detecting DCs in vivo was first explored in 2011 by Bonetto et al.102  In this work, they 
showed an intracellular uptake of 1.7x1013 19F/cell, the highest reported labeling 
efficiency to date.102 Using a spin density weighted SE sequence on a 7T system, a 
minimum of 2000 cells/voxel could be detected in phantoms.102  These results were 
extrapolated to provide an estimation of a minimum detection threshold of 30,000 
cells/voxel on a clinical 3T MRI,102 or around 5x1017 19F atoms.  
Another common application of 19F-MRI has been for imaging stem cell transplants. The 
field is well suited to 19F-MRI, since large numbers of stem cells are routinely 
administered in translational models.  Like with DCs, PFCs have been shown to not 
negatively influence stem cell surface markers, differentiation, or proliferation.56,103 
Using relatively simple transplantation models has allowed for groups to test and 
optimize more advanced 19F techniques.  An example of this is in 2007, Partlow et al. 
demonstrated that two-colour 19F-MRI could be used to distinguish separate populations 
of stem cells that had been labeled with different PFC agents.95  By selectively exciting 
each agent individually, the different cell populations could be imaged in sequential 19F 
scans.  
Immune cells can also be labeled in situ by i.v. administration of PFC, in the same way as 
described in Section 1.3.3.  However, with 19F-MRI this allows for both the inflammatory 
sites to be both spatially localized and the relative level of inflammation to be 
compared.74,75,104–107 In addition to the quantification potential, imaging inflammation 
with 19F-MRI produces few anatomical image distortions compared to iron oxide.  This is 
particularly advantageous when imaging arthritic inflammation around joints, where the 
negative iron contrast can be easily confused with the low proton density bone. In a study 
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by Balducci et al., 19F-MRI was used to assess longitudinal responses to an arthritis 
therapy.108  Inflammation as marked by 19F-signal was observed to increase in untreated 
controls, but 19F-signal remained constant in prednisolone treated animals.108 
Unfortunately no 19F clearance was observed overtime, despite the success of therapy as 
measured by other clinical responses.108 This highlights one of the drawbacks of using 
cellular MRI for longitudinal inflammatory imaging, macrophages are known to remain 
in the tissue for an extended period of time after the initial inflammation subsides. In 
addition to imaging inflammation near bone, cardiac tissue is another region where joint 
1H/19F MRI has an advantage over previous techniques. In 2008, Flogel et al. imaged 
inflammation following cardiac ischemia, showing a time dependence on the observed 
19F-signal between 1 and 6 days post ischemic event.75 This differed from results 
observed in a similar model using SPIO, where no difference in fractional signal loss was 
observed after 24 hours.13 This is likely due to the saturation of the signal loss that occurs 
with iron-oxide, and highlights the advantage of using 19F-MRI for quantitative analysis.    
19F MRI has also been utilized to image acute allograft rejection following heart 
transplantation in mice.107 Inflammation could be differentiated and quantified between 
the left and right ventricles of the heart,107 potential allowing for targeted interventions to 
be performed to prevent the organ from being rejected.   
1.4.1 Perflurocarbon Imaging Agents 
Due to the toxicity of ionic 19F atoms, imaging is predominately performed with 
biologically inert PFC.  These agents make use of the carbon-fluorine bond, the second 
strongest bond in organic chemistry, which cannot be naturally broken.109 This produces 
biologically safe, inert agents for imaging. In the 80’s, PFCs were evaluated as a blood 
substitute option in patients due to the high affinity for O2.110 In comparison, for cell 
tracking applications only minuet quantities of PFC are used, with clearance through the 
monocyte-phagocyte system and lung exhalation.111,112  
PFCs are generally produced by replacing hydrogen atoms on hydrocarbon chains and 
can be designed to be linear (perfluoropolyether [PFPE]) or cyclic (perfluoro-15-crown-
5-ether [PFCE]).  In either case, the ideal imaging agent possesses a high number of 19F 
atoms with a single resonant peak and a short T1 allowing for rapid imaging.  Table 3 lists 
  
18 
relaxation times at a variety of field strengths for commonly used 19F agents in cell 
tracking. 
Table 3: PFC relaxation rates vary with agent and field strength 
Agent 
Single 
Peak 
# 19F 
Spins 
T1 (ms) T2 (ms) 
PFPE No 28-36 
3T: 470112 
7T: 590,113 425114 
9.4T: 510113 
11.7T: 280,115 380115 
3T: 250112 
7T: 82114 
 
11.7T: 153,115 68115 
PFCE Yes 20 
7T: 2500,113 950100 
9.4T: 580,98 600,93 
1000116 
11.7T: 80097 
7T: 50100 
9.4T: 536,98 300,93 
350116 
At the moment there is only a single commercial PFC designed for cell tracking.  Based 
on a PFPE backbone, Cell Sense (CS-1000, CelSense Inc.) is produced under the Good 
Manufacturing Practices (GMP) required for clinical applications. As such it is the only 
commercially available, FDA-approved cellular MRI agent. For pre-clinical work, the 
agent is available in fluorescently tagged variants (CS-1000 DM-red), as well as in a 
form suitable for IV injection for in situ labeling of phagocytes (VS-1000). 
1.5 Purpose of Thesis 
Since 2005, numerous proof-of-concept studies have been performed with a variety of 
cell types in various disease models.  However, until recently, this work has been 
restricted to a handful of laboratories with the necessary combination of expertise and 
equipment.  The purpose of this thesis was to develop technology and implement the first 
19F-imaging site in Canada, capable of both pre-clinical and clinical cell tracking. 
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1.5.1 Hypotheses 
1. Transplanted cell number and spatial location can be non-invasively 
monitored with longitudinal 19F-MRI. 
2. Differences in stem cell fate can be detected between isograft and xenograft 
transplantation models with 19F-MRI. 
3. The combination of 19F-labeled stem cells and iron-labeled immune cells will 
allow for simultaneous MRI446 of transplant rejection.  
4. Clinical cell tracking will be feasible with 19F-MRI for a future cancer 
immunotherapy clinical trial.  
In Chapter 2, the development and implementation of small animal 19F-MRI is outlined 
for a 9.4T MRI system.  This work introduces and provides additional details for the pre-
clinical imaging protocols utilized by this thesis.   
In Chapter 3, the stem cell fate in two models of murine transplantation were investigated 
with 19F-MRI.  Validated with histology, this work shows that 19F-MRI is a powerful tool 
for non-invasive, longitudinal imaging. This chapter was published in PLoS ONE 
(Gaudet et al. Tracking the fate of stem cell implants with fluorine-19 MRI. PLoS ONE. 
2015 10(3):e0118544) 
In Chapter 4, the natural immune response to a rejected transplant was imaged with dual 
cellular MRI agents. Immune cells were tracked following in situ labeling with iron 
oxide, while stem cells were monitored with 19F-MRI. This chapter was published in the 
journal, Magnetic Resonance in Medicine (Gaudet et al. Application of dual 19F and iron 
cellular MRI agents to track the infiltration of immune cells to the site of a rejected stem 
cell transplant. MRM. 2016) 
In Chapter 5, a 19F-cell tracking imaging protocol was developed for an upcoming phase 
1 clinical trial.  This trial will involve the administration of APCs intradermally into the 
upper thigh of prostate cancer patients. Imaging was validated at 3T with a porcine tissue 
phantom. Sections of this chapter are under review at PLoS ONE (Fink et al. 19F-
perfluorocarbon-labeled human peripheral blood mononuclear cells can be detected in 
vivo using clinical MRI parameters in a therapeutic cell setting.) 
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Chapter 2  
2 Optimization of Preclinical 19F-imaging Techniques 
As the first 19F-MRI cell tracking site in Canada, a number of parameters and protocols 
required development and optimization prior to beginning animal studies.  This chapter 
provides additional details on the methods utilized in the following chapters for 19F 
acquisition, with a focus on minimum detection limit and quantification accuracy.  
2.1 Equipment 
Pre-clinical imaging was performed on a 9.4T Varian/Agilent small animal scanner.  The 
high-field system provides a number of advantages for 19F detection.  As discussed in 
Chapter 1, net magnetization increases with the field strength, so a 9.4T system provides 
more than 6x the signal of a clinical 1.5T MRI.  In addition, the smaller bore size 
provides more accurate shimming and allows for stronger gradient slew rates at small 
animal sizes.  All of these factors contribute to higher resolution and improved image 
quality in murine images compared to a clinical MRI system.  A 19F/1H dual-tuned 
birdcage volume coil, tuned to 376. MHz and 400.2MHz respectively, was produced in 
house by Kyle Gilbert. The volume coil has a 2.2cm diameter and 5.1 cm length, and is 
shown in Figure 3A, alongside the B1 map (Fig 3B).  The relatively uniform B1 field at 
the center of the coil provides more accurate cell quantification, further discussed in 
Section 2.3.  Coil diameter was kept as small as possible for murine imaging to optimize 
sensitivity. 
2.2 MRI Acquisition Parameters 
2.2.1 Pulse Sequence 
Overall, the vast majority of 19F-MRI studies have employed spin echo sequences.1 As of 
2012, only a single study had utilized bSSFP for 19F-cell tracking of pre-labeled cells.2 
Since then, the high signal-per-unit time advantage bSSFP provides has been used in 
numerous studies to investigate 19F-labeled MSC,3 NK cells,4 stromal vascular fraction 
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Figure 3: (A) Image of the dual tuned birdcage volume coil.  The tuning frequency is 
controlled by driving through one of the two coaxial cable connectors. (B) The 
Actual Flip angle Image (AFI) shows the field uniformity in the center of the 19F 
birdcage coil, with each circle representing a 5mm axial slice. The scale on the right 
indicates the actual flip angle applied to the same following application of a 90o 
pulse. 
 
cells,5 and inflammatory cells.6  Expanding on Section 1.3.3, bSSFP has additional 
advantages for multi-nuclear imaging compared to conventional sequences.7,8  The short 
imaging repetition time (around 4ms) allows for 100s of imaging averages to be 
performed in a reasonable scan time.  The high SNR produced improves detection 
sensitivity, but can also be traded off to allow for higher resolution, an advantage that is 
outlined in more detail in Section 2.2.2. When TR= 2*TE bSSFP images are not 
influenced by T2*, despite being formed by a gradient echo-like sequence. This is an 
important factor when considering quantification accuracy, since it relies on the 
assumption that image contrast is constant across the image.9,10 Finally, PFC agents tend 
to have relatively similar T1 and T2 values, providing the optimum steady state 
magnetization as given by Equation 4.1,10   All of these factors, as well as the extensive 
literature on iron cell tracking with bSSFP,11–15 influenced our decision to use the bSSFP 
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sequence for this thesis. To date SSFP-based pulse sequences have shown the best 19F 
sensitivity, with only ultra-short echo time (UTE)-SSFP producing higher signal then 
bSSFP.8      
2.2.2 19F Image Resolution 
In general, SNR is expected to increase with larger voxel size.  This is due to the fact that 
with conventional proton imaging, larger voxels contain more hydrogen nuclei, 
generating higher signal. However, with 19F-MRI cell tracking, larger voxels do not 
always lead to an increased SNR.  This is predominately due to the fact that voxel size is 
already orders of magnitude larger than the area taken up by the injected cells in vivo.  In 
this case, an increase in voxel size does not result in improved signal, since there are no 
additional 19F nuclei to excite in the surrounding area. Instead, when field of view is kept 
constant, larger voxels tend to decrease SNR due to increased under-sampling artifact.  
An example of this is shown in Figure 4, where detection of 20,000 cells in 2mm3 voxels 
(Fig 4A) is compared to 12mm3 (Fig 4B).  Overall though, voxel size does need to remain 
large compared to proton imaging to maintain sufficient 19F atoms/voxel. 
 
Figure 4: Cell pellets containing 20,000 (white arrow) and 60,000 (yellow arrow) 
cells. (A) SNR and image quality is higher, and quantification was found to be more 
accurate at 2mm3 resolution, compared to (B) 12mm3 voxels. 
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2.3 Quantification of Labeled Cells 
2.3.1 Theory 
Since signal produced by nuclear magnetic resonance is dependent on the number of 
nuclei per voxel, it is inherently quantitative.  Non-invasive, in vivo quantification of 19F-
labeled cells was first described in 2010, by Srinivas et al.16 The basic procedure is 
outlined in Figure 5. The first step towards quantification involves determining the 
intracellular 19F uptake, or mean fluorine content per cell (Fc). Following in vitro 19F-
labeling of the cells, a sample containing a known number of cells is set aside for NMR 
analysis (process 1). Samples were analyzed at the University of Western Ontario 
Chemistry NMR facility with a Mercury VS 400MHz vertical bore magnet.  Prior to 
spectroscopy, the NMR cell sample is suspended in D2O and combined with 100µL of 
0.1% trifluoracetic acid (TFA).  Each TFA molecule has three identical fluorine atoms, 
producing a single NMR spectrum peak at -76ppm. Using this information, Fc can be 
determined by comparing the ratios of the NMR peak integral between TFA and the cell 
sample. This calculation is shown in Equations 6-8. 
 #	19%	&'	(%) = 	 (,-./	01	23,	4./5)7(809.:	01	23,)(;<)  (eq.6)     
 (=>?@	#	19%	&'	AB@@C = 	 (,-./	01	D3E	4./5)(#FG3	HI	23,)   (eq.7)     
 %A = 	 (20J/9	#FG3	HI	K.99:)(#	01	K.99:)      (eq.8)      
The second process determines the number of 19F atoms present at the region of interest 
within the animal.  Imaging is performed alongside a reference tube of known 
concentration containing the same 19F Cell Sense agent. By comparing the signal ratios of 
these two locations, the number of 19F atoms at the ROI can be determined, as shown in 
Equation 8. 
  
 
Figure 5: In vivo quantification 
can be performed when labeling 
cells in culture prior to their 
administration.  Cells are 
labeled through co-incubation 
with a 19F-agent overnight to 
allow for 19F-spins to become 
internalized within cells.  
Labeled cells are then split into 
two separate pellets.  The first 
pellet undergoes process 1, 
where NMR is used to 
determine the mean 
intracellular 19F uptake. The second pellet is administered into the host, either a pre-clinical model or a patient.  Process 2 
involves conventional 1H imaging of the host to provide the high resolution anatomical images.  Then without moving the 
patient, 19F imaging is performed over the same field of view in process 3. These two images can be overlaid for anatomical 
context of the 19F signal. An external reference tube of known concentration is imaged alongside the host allowing for the 
signal from the labeled cells to be converted to number of 19F atoms.  By combining this information with the NMR data, the 
number of cells can be quantified
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Finally, by combining Equations 7 and 8 it is possible to determine the number of labeled 
cells present at the ROI, Equation 9. 
 #	B.CCD	%&	'() = (EFG	7<	9:;)(G@)   (eq.9)     
 
2.3.2 Improving Quantification Accuracy 
Calculations were performed using Voxeltracker software provided by CelSense Inc.17  
This imaging software simplifies the process by measuring signal and volume from hand-
drawn ROIs and provides an estimation of quantification error from the image noise. 
Initially, quantification accuracy was poor, displayed in Figure 6 as the error multiple 
from the expected number of cells on a log-scale. The software automatically applies a 
Rician noise correction to improve accuracy.  Unfortunately, this noise correction 
assumes the minimum noise distribution starts at 0.  This assumption is often incorrect as 
all voxels were found to contain some noise signal, as shown in Figure 6B.  By 
subtracting a constant signal value (x) from all voxels, the distribution can be left shifted 
back to the origin (Fig 6C).  This step significantly improved quantification accuracy 
between unadjusted (Voxeltracker) and subtracted data sets, as shown by Figure 6C.  
Simplifying the data set by converting to 8-bit was also investigated, which inadvertently 
left-shifted some datasets improving accuracy.  However, information lost by restricting 
to 256 bins hindered the robustness of the technique. 
Further improvements were made to NMR accuracy by lysing cells to release the 19F 
agent prior to NMR.  Without lysis, cells would sediment towards the bottom of the 
NMR tube, resulting in a non-uniform suspension and reducing the accuracy of the 
measurement.   
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Figure 6: (A) Quantification error from six experiments is expressed as an error 
multiple from the true value of 1 on a logarithmic graph.  The black bars indicate 
quantification error from raw un-adjusted data sets. (B) An image histogram of this 
data reveals that all voxels contain some signal value, an assumption that is not 
taken into account by the quantification software.  (C) Improved quantification 
accuracy is obtained by left-shifting the histogram by subtracting a fixed value, 
equal to that of the lowest signal voxel, from all voxels as shown in the red bars. 
Besides the methods described, 19F-MRI quantification has been demonstrated numerous 
times in the literature with custom MATLAB scripts allowing for improved noise 
corrections and automated thresholding.6,18–22  Extensive work has also been performed 
with MR spectroscopy to improve the accuracy and sensitivity of quantification, at the 
cost of image resolution.23–27 
Ultimately, a number of factors contribute to quantification error.  These include 
acquisition specific, such as: T1 and T2 differences between intracellular label and 
external reference tubes, error in power calibration due to the lower 19F signal, Bo/B1 field 
inhomogeneities; and at the cellular level, such as: uncertainty in cell number for NMR, 
inaccuracy in injection number, and distribution of label uptake. For longitudinal 
imaging, bystander labeling of native, non-targeted phagocytic cells provides the largest 
source of error, which is explored in more detail in chapters 3 and 4.  
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2.4 19F-Uptake 
The labeling efficiency, or amount of 19F per cell, is extremely important in determining 
the minimum number of detectable cells due to the fact that NMR signal is directly 
related to the number of nuclei within the voxel.  For example, 10,000 cells containing 
1x1012 19F atoms/cell produces the same signal as 1,000,000 cells containing 1x1010 19F 
atoms/cell. We observed intracellular uptake to be highly variable amongst cell batches, 
even in the controlled in vitro environment. The labeling variability is over orders of 
magnitude, as highlighted in Figure 7A, with each point indicating an experiment 
repetition.  Uptake is influenced by the cell type, cell size, phagocytic potential, and 
donor health, as well as the physical and chemical properties of the 19F agent itself. The 
Cell Sense (CS-1000) incubation concentration also influences the labeling efficiency 
(Fig 7B), but results in a decrease in viability at higher concentrations.   
 
Figure 7: (A) Number of mean 19F atoms per cell as measured by NMR was 
observed to vary by over two orders of magnitude within cell samples.  Each data 
point represents cells prepared for a unique experiment.  We found cells from older 
subjects tended to label less efficiently, in comparison to cells from younger subjects 
and culture. (B) Incubation concentration of the 19F-agent Cell Sense also influenced 
cellular uptake.  However, at 7.5mg the cell viability was observed to decrease (data 
not shown). 
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2.5 Anesthesia 
In order to reduce animal motion and stress most pre-clinical imaging relies on 
anesthetized animals. Isoflurane is the most common veterinary anesthesia in use, due to: 
the high tolerance, ease of administration through inhalation, flexibility of dosage, and 
availability.  However, due to the presence of 19F atoms, this anesthetic can produce 
unwanted 19F-MRI signal3,28 unless appropriate precautions are taken. Figure 8 presents 
the chemical structure of isoflurane alongside the 19F NMR spectrum from an 
anesthetized animal containing Cell Sense labeled cells.    
 
Figure 8: Each isoflurane molecule contains five 19F atoms (A). They are visible in 
the in vivo 19F spectrum of an anesthetized mouse (B, yellow arrow). Here the main 
CS-1000 peak is visible centered at 0 Hz (white arrow) [-91.5ppm], along with two 
isoflurane peaks [-86ppm and -81ppm]. 
In vivo, isoflurane accumulates in fat with a fat/blood ratio of 45.29 This is visible in 19F-
MRI images of a mouse (Fig 9A), imaged alongside a reference tube containing Cell 
Sense.  Imaging was performed centered at the Cell Sense frequency, resulting in a 
spatial shift in the isoflurane signal from the fat pad. Here the default truncated sinc 
excitation pulse was used (Fig 9B).  Excitation of the isoflurane signal can be prevented 
with a longer, un-truncated sinc pulse (Fig 9C&D). Following fourier transform; the 
longer sinc pulse translates into a narrower rectangular excitation band in frequency 
space.  When centered on the Cell Sense frequency, this band is narrow enough to not 
excite the nearby isoflurane peaks.   We used this approach for all of our animal imaging. 
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Figure 9: (A) Isoflurane signal (red arrow) is visible within the body of the mouse.  
This signal is spatially offset from its true location in the fat pad (blue arrow) due to 
the center frequency being locked on Cell Sense.  (B) The default truncated sinc 
pulse is narrower in temporal space then the sinc pulse (D).  After fourier transform 
the wider sinc pulse produces a narrower rectangular shape in frequency space, 
preventing the excitation of isoflurane (C). 
2.6 Two-colour 19F-MRI 
Building on the same principle as avoiding isoflurane excitation, distinct 19F peaks can be 
selectively excited in sequential acquisitions to provide two-colour 19F-MRI.  First shown 
in 2007 by Partlow et al., stem cells were labeled with either a PFOB or PFCE based 
nanoparticle.2 This method allows for distinct cell populations to be identified and  has 
applications in tracking multiple systems simultaneously.  In Figure 10, data from a pilot 
experiment shows the i.v. distribution of Cell Sense (red) mapped alongside the 
isoflurane distribution (green).  It was particularly interesting to note that this data shows 
that both Cell Sense and isoflurane are present in the liver. Although two-colour MRI 
was not utilized in this thesis, the technique has strong potential for application in the 
future directions of this work. 
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Figure 10: By employing the narrow peak selective pulses, the distribution of i.v. 
Cell Sense (red) can be imaged separately from isoflurane (green).  The two 19F 
images were then combined with an anatomical image. 
2.7 Common Artifacts 
The most common artifact observed in 19F-MRI cell tracking is the point spread function 
(PSF) resulting from under sampled imaging. The artifact is especially prominent in 19F-
cell tracking due to the strong signal produced by a point source of cells, and the lack of 
background.  PSF results in characteristic linear lines of noise in all three dimensions 
centered on the point source, as shown in Figure 11. 
This artifact can be reduced by increasing acquisition matrix size. However, due to the 
relatively low number of 19F atoms located within each voxel, as well as the importance 
of detecting all of these atoms for accurate quantification, lower resolution is preferable 
for 19F imaging (on the order of mm3 for pre-clinical systems).  In order to keep voxel 
size large enough for detection, the field of view can be increased to extend beyond the 
animal.  Unfortunately, this results in an increase of “dead-space” imaging, where no 
animal is present, along with the increase in imaging time associated with a larger 
acquisition matrix.  The work presented in this thesis has attempted to balance acceptable 
PSF image artifact with reasonable scan time. 
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Figure 11: Point spread function artifact produced by a region of high intensity 
signal. The artifact complicates image analysis, particularly when comparing signal 
between structures in the opposite side of the animal.  
Chemical shift artifacts are the second most commonly observed in images.  This artifact 
appears as a 1-2 voxel shift in spatial location between matched proton and fluorine 
images. These occur when the 19F imaging frequency is offset from the Cell Sense peak 
frequency, as shown with the isoflurane signal in Figure 8.  Luckily, post-processing 
correction of the artifact is simple by aligning the reference tubes in the 19F and 1H 
images.  
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Chapter 3  
3 Tracking the Fate of Stem cell Implants with Fluorine-19 
MRI† 
3.1 Introduction 
Stem cell therapy has the potential to play an important role in regenerative medicine.  
Mesenchymal stromal/stem cells (MSCs) have been extensively investigated for clinical 
application over the past decade.1,2 MSCs are capable of differentiating into a variety of 
important tissues, such as: bone, cartilage and adipose.3 They also display 
immunomodulatory properties.4–6 Their presence in adult tissue, and ease of expansion in 
vitro has made MSCs good candidate cells for clinical translation.7,8  
To advance stem cell therapy, there is a desire to develop tools to monitor the survival of 
implanted stem cells non-invasively after administration to the patient.  Magnetic 
resonance imaging (MRI) cell tracking is an effective method to visualize and monitor 
cells non-invasively after implantation due to the high spatial resolution and lack of 
ionizing radiation.   
The majority of MRI cell tracking studies have used iron oxide nanoparticles to label the 
cells of interest.9–15  When imaged with MRI, the iron nanoparticles produce a dark signal 
void in T2 and T2* weighted proton images.  This technique is highly sensitive, 
permitting the imaging of single cells.16,17 Limitations with tracking iron-labeled cells 
arise from low specificity, due to other regions in the image with low signal, and from 
complicated in vivo quantification of the signal loss. Our group and others have shown 
that the degree of signal loss produced by iron labeled cells is only linear at low iron 
concentrations.16,18 Furthermore the high sensitivity to iron can produce ambiguity due to 
___________________ 
†This chapter was previously published and is included here with permission and minor 
revisions: Gaudet JM, Ribot EJ, Chen Y, Gilbert KM, and PJ Foster (2015) 
“Mesenchymal stem cell transplant rejection monitored with 19F-MRI,” PLoS ONE 10(3): 
e0118544. 
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the strong false-positive signal produced when even a small number of bystander cells 
become labeled inadvertantly.19,20 
As an alternative to iron-oxide cell tracking, fluorine-19 (19F) MRI with perfluorocarbon 
(PFC) nanoemulsions has been used for cell tracking.21 19F MRI is able to image 
implanted cells with high specificity due to the lack of detectable fluorine in biological 
tissue.22,23 Quantification of implanted cells is possible since the 19F MRI signal intensity 
is linearly related to the number of 19F-labeled cells.  Unlike PET/SPECT probes, 19F 
does not undergo radioactive decay allowing for longitudinal studies without radiation-
induced toxicity to the implanted cells or surrounding tissue.  Furthermore, the first 
clinical application of 19F-MRI cell tracking for DC immunotherapy was recently 
reported, showing the technique is both feasible and safe for human application.24 
In this paper, we investigated the feasibility of quantifying MSC fate in two different 
immune environments.  This was performed by comparing the change in 19F-MRI signal 
strength over time using two popular transplantation models. A syngeneic transplant 
model, with mouse MSCs (mMSC) implanted in an immune-competent mouse host, was 
compared to a xenograft model produced from human MSCs (hMSC) implanted in an 
immune-compromised mouse.  Our goals were:  i) to quantify the apparent cell number 
non-invasively for 2.5 weeks and ii) to validate in vivo 19F-MRI quantification results 
with fluorescence microscopy and immunohistochemistry. 
3.2 Methods 
3.2.1 MSC Culture and Labeling 
hMSC came from bone marrow donated by healthy young adult volunteers after written 
informed consent according to a protocol approved by University Health Network 
Research Ethics Board (Toronto, Canada)25. hMSC were cultured as described by Ribot 
et al.19 Briefly, hMSC were grown in low glucose Dulbecco’s Modified Eagle’s Medium 
until passage 4. mMSC initially derived from the bone marrow of C57Bl/6 mice and 
expressing green fluorescence protein (GFP+) were purchased from Cyagen Bioscience 
Inc. (Catalog # MUBMX-01101). The cells were cultured in OriCellTM Mouse MSC 
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Growth Medium until 90% confluent.  The mMSC were passaged once before labeling 
and implantation. 
MSC were labeled with the red fluorescent perfluoropolyether agent, Cell Sense (CS-
ATM-DM Red; CelSense Inc. Pittsburg, USA)26.  Labeling took place over 24 hours at a 
concentration of 2.5mg/mL. After incubation, the cells were washed 3 times with Hank’s 
balanced salt solution (HBSS), harvested with Trypsin, spun down and counted.  At this 
stage the cells were tested for viability using trypan blue exclusion. Intracellular 19F 
content of cells was determined using NMR spectroscopy, as we have described 
previously.19 
3.2.2 MSC Implantation 
1.5x106 Cell Sense-labeled hMSC in 100µL of HBSS were implanted intramuscularly 
into the right hindlimb muscle of immune-compromised, nude mice (nu/nu, Charles 
River Canada) to produce a xenograft model (n=7). In a similar manner, 2.0x106 labeled 
mMSC in 100µL of HBSS were implanted into immune competent, C57Bl/6 mice 
(Jackson Laboratories) producing a syngeneic model (n=8). In both cases, the injections 
were performed under 2% isoflurane anesthesia. All experiments involving human and 
mouse stem cells, as well as animal use, were approved by the Western University 
Animal Use Committee (AUP 2009-042).  
3.2.3 MRI 
All images were collected using a 9.4T Varian small-animal MRI scanner. A 3D 
balanced steady state free precession (bSSFP) sequence was used for both proton and 
fluorine imaging. Cell pellets containing 2x105, 4x105, 6x105, 8x105, 1x106 and 2x106 
19F-labeled MSC were imaged alongside a CS-1000 reference tube of known fluorine 
concentration (7.3x1016 19F/µL).  MRI was performed using a dual-tuned birdcage 
volume coil (diameter 2.2cm, length 5.1cm), tuned to 400.2 MHz and 376.8 MHz for 
proton and fluorine imaging respectively.  For proton imaging of cell pellets the scan 
parameters were: repetition time (TR)=3.8ms, echo time (TE)=1.9ms, receiver bandwidth 
(rBW)=125kHz, flip angle (FA)=30°, averages=2, resolution=200x200x200µm3.  For 
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fluorine imaging the parameters were: TR=3.5ms, TE=1.8ms, rBW=25kHz, FA=70°, 
averages=250, resolution=1x1x2mm3. Total protocol time for both proton and fluorine 
imaging was under 90 minutes.  The pellets were imaged on three separate occasions to 
test quantification variability. 
Mice containing 19F-labeled MSC implantations were imaged at four time points, starting 
on day 0, after implantation. The scan parameters were the same for the in vivo mouse 
MRI as described above. During scanning the mice were anesthetized with 2% isoflurane, 
with breathing rate and temperature monitored.  Due to the high sensitivity of bSSFP to 
off-resonance frequencies27, a narrow 1.5kHz sinc pulse was used to excite only the 19F 
agent. 
3.2.4 Image Analysis and Quantification 
Prior to image analysis, a signal correction was applied to the 19F datasets by subtracting 
a constant value (x) from all voxels within the dataset using the image program, 
ImageJ.28,29 The value of x was equal to the signal of the single voxel containing the 
lowest signal throughout the entire dataset. This linear translation acted to left-shift the 
data distribution to begin at zero. Quantification was performed using Voxel TrackerTM 
software, as described by Srinivas et al.30 Briefly, in the 19F MR images, the signal 
contained within a hand drawn ROI is summed and compared to the average signal 
produced by the reference tube of known concentration (2.6x1016 19F spins/µL). This 
value (X) provides the total number of 19F spins located at the ROI. NMR spectroscopy 
was then performed using a known number of the same transplanted cells, along with a 
second 19F source containing a known number of 19F spins. By comparing the relative 
NMR signals, the number of 19F spins per cell (Y) is obtained. Division of X by Y yields 
the number of cells located at the ROI. Significance between time-points was assessed 
using a repeated measures, one-way ANOVA. 
3.2.5 MSC Immunohistochemistry 
Mice were sacrificed and perfused with 4% paraformaldehyde following the final 
imaging timepoint. In addition, one mouse from each model was sacrificed and perfused 
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on Day 0 for comparison.  The hindlimb muscle was extracted and cryoprotected with 
increasing concentrations of sucrose (10%, 20%, 30%) before freezing in OCT medium.  
Tissue was sectioned with a cryostat.  Fluorescence microscopy was performed to image 
the red fluorescent 19F-label as well as the GFP+ mMSC with a Zeiss AXIO Imager 
microscope (Carl Zeiss Canada Ltd). Immunohistochemistry staining was then performed 
on these sections. Macrophage presence was assessed using Biotin anti-mouse 
macrophage (F4/80) monoclonal antibody (Cedarlane Laboratories Ltd) with 3,3’-
Diaminobenzidine (DAB) counterstain.  
3.3 Results 
In vivo results 
Figure 12A shows that labeling with the 19F agent did not negatively affect the mMSC 
cellular viability.  The viability of the hMSC was slightly decreased following labeling. 
Previous work by our group demonstrated that the perfluorocarbon, Cell Sense, does not 
negatively impact differentiation of labeled hMSC into osteogenic or adipogenic 
lineages.19 NMR revealed the mean cellular loading of 19F varied between experiments 
and cell types within the range of 8.2x1010 to 2.4x1011 atoms. 
Quantification of 19F in cell samples 
Quantification of the 19F signal was tested in vitro using Cell Sense labeled mMSC 
pellets.  Imaging was performed at 9.4T on six cell pellets ranging from 200k to 2 million 
cells. Figure 13 represents the average quantification and standard deviation from 
imaging the cell pellets on three different occasions. We observed a strong linear 
relationship between the MR quantification and the real cell number, with an R2=0.98.  
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Figure 12: (A) Cellular viability was investigated before and after labeling with the 
19F-agent, Cell Sense.  Although a statistically significant difference was observed in 
hMSC after labeling, the viability remained high (>80%) in all experiments.  There 
was no significant difference in mMSC viability.  (B) Mean cellular loading was 
determined by performing NMR spectroscopy on a known number of cells alongside 
a reference peak with a known number of 19F atoms. We observed variation in 
cellular loading of both hMSC and mMSC between experimental batches.  
However, this variation does not affect in vivo 19F quantification since each 
transplant was only compared to its specific cellular loading. 
In vivo detection of 19F MRI signal 
19F-MRI signal was initially detectable in all mice following intramuscular injection of 
2.0x106 mMSC or 1.5x106 hMSC. On day 0 quantification of the in vivo signal agreed 
very well with the number of implanted cells (Fig. 14). Over time the signal decreased in 
both models.  In the immune competent model (Fig. 14A), a significant difference was 
observed in the 19F MRI signal over time [F(1.703,6.812)=39.85, p<0.001]. Post hoc 
Tukey tests showed there was a significant difference in 19F signal between day 3 and day 
9 (p<0.01), and day 9 and 16 (p<0.05). At 16 days post implantation only two mice had 
any detectable signal remaining.   Signal in the immune-compromised mice (Fig. 14B) 
decreased more slowly [F(1.378,5.511)=30.97, p<0.01], with significance from day 0  
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Figure 13: in vitro validation of 19F-MRI quantification accuracy. Quantification 
was validated in a phantom study using cell pellets ranging from 2x105 to 2x106 
MSC. Pellets were imaged three times, with the error bars representing the 
standard deviation between scans.  The 19F-MRI quantification is in very strong 
agreement with the true number of cells, and has a Pearson correlation coefficient of 
0.99.  The red line represents the ideal result of a 1:1 correlation. 
 
Figure 14: Comparison of 19F-labeled cell detection in two transplantation models 
over time (A) Following implantation of 2x106 mMSC, 19F-MRI was used to quantify 
the number of cells remaining over 16 days. By day 16, only 2/7 mice had any 
detectable signal remaining. A significant difference from day 0 is denoted by , 
from day 3 by u, and from day 9 by n. (B) The number of detectable cells over a 
similar time period following a transplant of 1.5x106 hMSC. 19F signal was found to 
decrease at a slower rate, with observable signal in all mice at the endpoint. 
Statistical significance is denoted in the same way as A. 
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only detectable on day 17 (p<0.01).  Furthermore, at this endpoint all immune-
compromised mice still had detectable signal.  
Representative MR image data, fluorescence microscopy, and H&E obtained on day 0 is 
shown in Figure 15. Overlays of the 19F MRI onto the proton image at day 0 are shown in 
15A and E for the immune competent and immune compromised mice, respectively. 
Figures 15B and F show that the red fluorescence signal from the 19F labeling agent can 
be detected on day 0 in both models.  The green fluorescence associated with the GFP+ 
mMSC was also visible at the site of their implantation on day 0 (Fig. 15C).  Overlaying 
the two fluorescent images revealed co-localization, with a Pearson’s correlation 
coefficient of 0.80, between the red fluorescent 19F agent and the GFP+ mMSC in Figure 
15D. The corresponding H&E stained tissue sections agree with the location of the 
implant within the muscle (Fig. 15G,H). 
Figure 16 shows representative MR image data, H&E, F4/80 immunohistochemistry and 
fluorescence microscopy obtained at the experimental endpoint. By day 16 post 
implantation no 19F-MRI signal from the mMSC was detectable in 5/7 of the immune 
competent mice. One of these mice is shown in Figure 16A where the only 19F signal 
comes from the reference tube. In contrast, 19F signal was still detectable in all of the 
immune compromised mice at day 17, with an example shown in Figure 16E. 
Fluorescence microscopy revealed only a small area of red fluorescence from the 19F 
agent in the immune competent model (Fig. 16B) compared to the immune compromised 
(Fig. 16F).  In addition, no GFP+ mMSC were detectable in ex vivo samples at endpoint.  
H&E staining of the same tissue sections showed cells at the site of the implant, which 
corresponded with the 19F agent’s red fluorescence (Fig. 16C,G).  Neighboring tissue 
sections corresponding to high red fluorescence were stained for the presence of 
macrophages using F4/80. Figure 16D suggests that relatively few macrophages were 
detected in the immune competent model at endpoint. In contrast, the F4/80 stain 
revealed macrophages (Fig. 16H) in the same region as the red fluorescence from the
  
 
Figure 15: (A, E) Representative MRI from mice receiving either 2x106 mMSC or 1.5x106 hMSC respectively.  The day 0 in 
vivo 19F-MRI quantification correlates very well with the number of implanted cells. The reference tube is marked by “R”. (B) 
The red fluorescent fluorine agent is clearly visible in the tissue of the immune competent model, (F) as well as in the immune-
compromised model. (C) Furthermore, the GFP+ mMSC are observable within the tissue section. (D) Overlaying the two 
fluorescent images, reveals the 19F agent colocalized with the GFP+ mMSC, as expected. (G, H) H&E stained tissue sections 
corresponding to the fluorescence microscopy clearly show the implant site of the mMSC and hMSC respectively. Scale bars 
in all images represent 250µm
  
Figure 16: By day 16, 5/7 immune competent mice had no 19F-MRI signal remaining (A). The reference tube is marked by 
“R”. (B) Fluorescence microscopy of the muscle agreed with little red fluorescence. No GFP+ mMSC were detectable by 
fluorescence microscopy, suggesting the original mMSC are no longer present.  (C) H&E staining reveals cells at the implant 
site which correlates with the remaining 19F red fluorescence. (D) Immunohistochemistry staining of adjacent tissue sections 
with the anti-F4/80 antibody reveals a few macrophages at this location in the immune competent model.  (E) At endpoint, all 
immune compromised mice had detectable 19F-MRI signal remaining. (F) More red fluorescence is visible, and (G)H&E 
staining again correlates well with the regions of red fluorescence. (H) Macrophage staining reveals many more F4/80 positive 
cells at the site of implantation corresponding to the regions of red fluorescence. Scale bars represent 250µm. 
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19F agent in the immune compromised model. The number of macrophages visually 
corresponded with  the amount of remaining red fluorescence in both cases. 
3.4 Discussion 
In vivo quantification of MSC  
This study demonstrates the ability to use 19F-MRI cell tracking to detect and, most 
importantly, to measure the signal from transplanted stem cells in vivo. It is difficult to 
quantify cell number using other MRI cell tracking techniques.  Numerous studies have 
previously reported on the challenges associated with quantification of signal loss due to 
iron-labeled cells.19,20,31 This has, so far, narrowed the implementation of cell tracking for 
monitoring the fate of transplanted cells.  In this study, we show excellent correlation 
between the number of labeled cells implanted and the number of cells counted on day 0 
by 19F-MRI.  This capability will pave the way for MRI to be used in confirming the 
delivery of therapeutic cell transplants.  
The importance of accurate delivery of cells to a target tissue cannot be overstated.  In 
preclinical investigations often stem cells will be transplanted then a set time allowed to 
lapse before the transplanted tissue is removed and processed for microscopy, to 
determine whether stem cells remain in the tissue.  In many cases, only a very small 
sample of the transplanted tissue is evaluated.  In a previous study we used MRI to track 
iron-labeled MSC in a mouse model of spinal cord injury32.  Our in vivo imaging revealed 
that the challenging intrathecal injections of MSC were imprecise approximately 25% of 
the time; injected cells were often being deposited in tissue above the cord or leaking out 
of the cord. The histological assessment in this study involved the analysis of 1cm of cord 
tissue on either side of the transplant site, six weeks after transplantation. Without MRI, a 
negative observation of MSC by microscopy would have been taken as failure to engraft 
rather than due to a missed injection.  Injection confirmation with 19F MRI would have 
the additional advantage of determining how many cells were properly injected and 
remain at the site. 
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In a first-in-man study, MRI and scintigraphy were used to assess the success of 
intranodal injections consisting of a 1:1 mixture of iron- or indium-labeled dendritic cell 
(DC) for cancer therapy in melanoma patients.33  Despite these cell injections being 
performed under ultrasound guidance the MRI of iron-labeled DC revealed that in 3/8 
cases DC were injected near, but not in, the target lymph nodes.33 These findings make it 
clear that the outcome of this cell therapy on these patients would not be properly 
evaluated without knowledge of proper delivery of DC to the nodes. For DC therapy 
knowledge of the number of cells delivered to a lymph node is especially critical since 
DC migration to nodes correlates with effective stimulation of T cells.  19F-MRI therefore 
presents a promising solution to the clinical problem of verifying both the location and 
number of cells within the region of interest immediately following administration of 
treatment. 
In these experiments the hMSC and the mMSC were both capable of taking up sufficient 
19F label for in vivo detection, without decreasing viability below 80%.  We observed 
some variation in the number of 19F atoms loaded per cell between experiments, although 
the average loading was not significantly different for mouse versus human MSC. The 
cell size is one of the more important factors influencing the labeling with Cell Sense and 
mouse and human MSC are approximately 30 microns in diameter. The fact that it is 
possible to obtain robust measurements of the number of cells detected by MRI, despite 
inter-experiment variation in the number of 19F atoms per cell, is another positive feature 
of this type of cell tracking. The variation in 19F/cell between batches is not a 
confounding factor in the 19F-MRI quantification since the mean cellular loading is 
determined for each transplantation. This is particularly important when considering 
clinical translation, since 19F uptake is expected to vary between cell donors. 
Monitoring the fate of MSC over time 
This study also revealed some interesting information about tracking cell fate over time 
with 19F MRI.  We studied the fate of MSC in two different models: mMSC implanted 
into healthy wild type C57Bl/6 mice (immune competent model) and hMSC implanted 
into healthy nude mice (immune compromised model). We believe the MSC and 19F-
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label, underwent clearance from the sites of implantation in muscle at different rates, 
which is not unexpected since the two different mouse strains have very different 
immune systems.  
In the immune competent model, 5/7 mice had no MRI detectable 19F signal remaining at 
the site of injection by the endpoint. The other 2 mice had just 4% and 10% of the 
original signal remaining. There were no GFP+ cells detected by fluorescence 
microscopy but there was some red fluorescence, indicating that some of the 19F label 
persisted at the site but that it was not within GFP+ mMSC. The small amount of residual 
red fluorescent signal corresponded with F4/80 staining suggesting that some transfer of 
19F label from mMSC to macrophages has occurred. The decline in the signal is likely the 
result of several different things happening at the transplant site. First, many MSC will 
die early after their direct transplantation into a tissue.  Second, the label may be diluted 
by MSC proliferation, or degradation of the label within MSC. Third, MSC may have 
migrated away from the implant site; although we did not detect 19F signal in other 
nearby locations. 
The fact that for 5/7 mice no endpoint MRI signal was detected, even though red 
fluorescence was still observed in the tissues (as for the example shown in Fig 16A-D) is 
most likely because the number of cells containing the red fluorescent 19F label is very 
small. This small amount of 19F signal is below the in vivo detection limits of the MRI 
protocols used in this study.  
In the immune compromised model the 19F signal persisted in all mice until the 
experimental endpoint.  Much more red fluorescence was observed in these tissues at the 
implant site and this corresponded well with F4/80 staining, again suggesting that the 
persistent 19F signal was related to transfer of label from hMSC to macrophages. A 
limitation of this study was that our hMSC were not also GFP+. This would have allowed 
us to say with more confidence that the 19F label was associated with macrophages and 
not the implanted hMSC. Clearance of label and macrophages may have been slower in 
these mice because of the inhibited immune system and lack of rejection response.  
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Our observation of bystander cell uptake of 19F cell label is supported by a study by 
Boehm-Sturm et al.34 In their study in vivo imaging of the location, density, and survival 
of neural stem cells implanted in the brain in a stroke model was performed using 19F 
MRI in combination with bioluminescence imaging.  The signal from 19F labeled stem 
cells persisted for more than 4 weeks after implantation while, over the same time period, 
the bioluminescence declined, indicating stem cell death.  Immunohistochemistry 
staining also revealed the presence of microglia/macrophages at the site of implantation. 
Terrovitis et al. looked at the retention of iron labeled stem cells implanted into immune 
competent rats.20 Either rat or human cardiac-derived stem cells were injected 
intramyocardially.  In both cases MRI signal loss due to iron was detected for 3 weeks 
post cell injection and correlated with the presence of iron containing macrophages in 
histology.  Although the area of signal void decreased over time, substantial signal void 
persisted at the injection site in all mice. Since proton MRI is sensitive to even small 
numbers of iron-labeled cells this form of cell tracking is most susceptible to the 
misinterpretation of cell fate. Previous studies performed in our lab using iron labeled 
syngeneic MSC also revealed the persistence of an iron signal void past 21 days in 
immune competent mice.14  
3.5 Conclusions 
In summary, 19F MRI can be used to provide immediate assessment of implanted cells 
with excellent correlation between implanted cell number and in vivo quantification.  
Over time, as the cells are cleared from the transplantation site, transfer of the 19F label to 
bystander cells may confuse interpretation of the change in 19F signal.  With the first-in-
man studies of 19F MRI recently completed, this result will be particularly relevant when 
translating this technique into the clinic.24  
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Chapter 4  
4 Application of Dual 19F- and Iron-Cellular MRI Agents to 
Track the Infiltration of Immune Cells to the Site of a 
Rejected Stem Cell Transplant‡ 
4.1 Introduction 
Cellular magnetic resonance imaging (MRI) has proven to be an effective technique for 
non-invasive tracking of cellular therapeutics.  The absence of signal attenuation with 
tissue depth and the lack of ionizing radiation allows for long-term monitoring without 
risk to the patient or therapeutic cells. MRI cell tracking relies on pre-labeling cells with a 
non-invasive imaging agent to render them MRI detectable.  To date, most cellular MRI 
has been performed with one of two labeling agents. The first, and most common, is 
superparamagnetic iron oxide (SPIO) nanoparticles.  Iron-labeled cells are indirectly 
detected as a region of signal void.  When subjected to an external magnetic field, SPIOs 
change the net local magnetization.  This acts to increase the R2* relaxation rates of the 
surrounding nuclear spins.  In the MR image, this results in signal loss or regions of 
hypointensity. Iron-based cell tracking has the advantage of being highly sensitive, due to 
the large magnetic field inhomogeneity effect produced by SPIO which is indirectly 
detected through the abundant water proton signal; a so-called blooming artifact.  Single 
cell imaging has previously been demonstrated with iron agents1,2.  The technique is 
limited by the challenges associated with quantifying signal loss, due to the non-linear 
relationship with iron concentration3.  This makes it difficult to quantify cell number and 
track changes in cell number over time.   
___________________ 
‡This chapter was previously published and is included here with permission: Gaudet JM, 
Hamilton AM, Chen Y, Fox MS, and PJ Foster (2016) “Application of dual 19F and iron 
cellular MRI agents to track the infiltration of immune cells to a site of a rejected stem 
cell transplant” Journal of Magnetic Resonance in Medicine. Early view online 
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Over the past decade, fluorine-19 (19F) based cell tracking techniques have become of 
increased interest4. Utilizing the MRI sensitive 19F nuclei, this method involves the direct 
measurement of signal from 19F spins and has no effect on proton contrast.  Since 
biological tissue has negligible levels of 19F, no background signal is present and the 19F 
signal is inherently quantitative.  However, the relative insensitivity of the nuclear 
magnetic resonance signal means that thousands of cells per voxel are required for 
detection.  The minimum number of cells required for detection varies between cell types 
depending on intracellular 19F uptake; which ranges between 1010-13 19F/cell. 
A major focus of MRI cell tracking has been on understanding the in vivo behaviour of 
transplanted stem cells5,6.  Prior to implantation, stem cells are labeled with an MR 
imaging agent in culture. Iron and 19F-based agents have both been utilized to investigate 
the location, migration and survival of stem cells 7–10.  With applications in neural, bone, 
cardiac, and cartilage reconstruction, stem cells have a high potential for therapeutic 
application.  In addition to cell restoration, recent studies have highlighted the important 
role stem cells play in promoting growth within the local microenvironment through the 
secretion of trophic factors11–13. Unfortunately, this therapeutic potential is often limited 
due to stem cell death.  In the days following administration, many stem cells undergo 
apoptosis due to the stresses of administration and inadequate access to nutrients12,14–17.  
Cytokines released by the apoptotic stem cells attract macrophages to the implant site, 
triggering an immune response by the host18–20. The immune cell infiltration occurs 
rapidly, often within the first week after transplant21.   
A number of studies have now demonstrated that tracking iron-labeled stem cells with 
MRI cannot be used to reveal graft rejection in vivo8,22–28. This is because it is not 
possible to reliably distinguish between live and dead iron-labeled cells in MRI. Bernau 
et al. shows that the death of iron-labeled human neural progenitor cells transplanted into 
the rat brain could be identified in vivo by bioluminescence imaging (BLI) but not by 
MRI; the BLI signal decreased below a detectable level with cell death while the MRI 
signal remained the same due to transfer of the iron label to bystander macrophages26. 
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Another cellular MRI strategy for detecting rejection has been to image the immune cells 
that infiltrate a failed graft. Here, iron particles are administered i.v. and engulfed by cells 
of the reticuloendothelial system. MRI is typically performed one day later to visualize 
the accumulation of iron-labeled cells, mainly macrophages and monocytes, at the site of 
the transplantation. A significant decrease in the MR signal intensity indicates rejection 
has occurred. This approach was first used to detect acute rejection in a model of rat renal 
transplantation in 200029. Since then, numerous studies have investigated the application 
of i.v. iron for detecting organ and stem cell rejection29–32. The potential for clinical 
translation of this technique has been recently demonstrated with the clinical i.v. 
administration of an ultra-small SPIO (USPIO), ferumoxytol33,34. 19F agents have been 
used in a similar manner within pre-clinical models for imaging inflammation35–38.  
The purpose of this study was to investigate the use of 19F- and iron-based cellular MRI 
techniques in concert to simultaneously monitor transplanted stem cells and infiltrating 
macrophages. Human mesenchymal stem cells (hMSC) were labeled with a 19F agent 
prior to intramuscular implantation into the mouse hind-limb and macrophage infiltration 
resulting from rejection of the transplant was visualized by in situ labeling with i.v. 
administered USPIO nanoparticles. 
4.2 Methods 
4.2.1 hMSC Culture and Labeling 
hMSC were collected from the bone marrow of healthy, young adult volunteers donated 
with written informed consent according to a protocol approved by University Health 
Network Research Ethics Board (Toronto, Canada)39. The cells were cultured in low-
glucose DMEM with 10% (Thermo Fisher Scientific Corp, Waltham, MA, USA) until 
90% confluent.  
hMSC were labeled with the red fluorescent perfluoropolyether agent, Cell Sense (CS-
1000-ATM:DM Red, CelSense Inc., Pittsburgh, USA)40.  Labeling took place over 24 
hours at a concentration of 2.5mg/mL. After incubation, the cells were repeatedly washed 
with Hank’s balanced salt solution (HBSS) before and after TrypLETM dissociation.  The 
viability of the isolated cells was tested by trypan blue exclusion. Intracellular 19F content 
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of cells (Fc) was determined using NMR spectroscopy, as we have described 
previously28. 
4.2.2 hMSC Implantation 
1x106 Cell Sense labeled hMSC in 50µL of HBSS were implanted intramuscularly into 
the right hindlimb muscle of 14 immune competent, C57Bl/6 mice (Jackson Laboratories, 
USA), as shown in figure 17. This model was utilized to promote a strong immune 
response against the human cells by the host. The injections were performed under 2% 
isoflurane in 100% oxygen anesthesia. 24 hours after hMSC implantation, the mice were 
randomly assigned to one of two groups.  Group A (n=7) received no further treatment. 
Group B (n=7) received 0.5mmol/kg of the ferumoxytol Feraheme (AMAG 
Pharmaceuticals, Waltham, USA) i.v. via tail vein 24 hours after the hMSC implantation. 
Two additional groups of 3 mice were used for controls. Group C (n=3), received 50µL 
HBSS on Day 0 instead of hMSC, followed by 0.5mmol/kg of Feraheme i.v. 24 hours 
later. Group D (n=3) received 1x106 unlabeled hMSC, followed 24 hours later by 200uL 
of i.v. 19F agent (VS-1000, CelSense Inc., Pittsburgh, USA). All experiments involving 
human stem cells, as well as animal use, were approved by the Western University 
Animal Use Committee.  
4.2.3 MRI 
All images were collected using a 9.4T Varian small-animal MRI scanner. A 3D-
balanced steady state free precession (bSSFP) sequence was used for both 1H and 19F 
imaging. Animals were imaged alongside an agarose diluted Cell Sense reference tube of 
known 19F concentration (3.33x1016 19F/µL).  MRI was performed using a dual-tuned 
birdcage volume coil (diameter 2.2cm, length 5.1cm), tuned to 400.2 MHz and 376.8 
MHz for 1H and 19F imaging, respectively.  For 1H imaging the scan parameters 
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Figure 17: Human MSC were labeled with a 19F agent prior to being implanted into 
the mouse hindlimb muscle. Quantification of the 19F signal performed at this 
timepoint shows a strong correspondence with the expected number of cells. 2) One 
day after implantation, iron nanoparticles were administered i.v. These 
nanoparticles are scavenged from the bloodstream by macrophages and monocytes, 
rendering them MRI detectable. 3) Two days after implantation, iron labeled 
macrophages have migrated to the site of implant. The labeled macrophages are 
visible in MR images as signal voids at the site. 19F-MRI signal is also significantly 
decreased as the iron quenches the signal. 
were: repetition time (TR)=5.0ms, echo time (TE)=2.5ms, receiver bandwidth 
(rBW)=78kHz, flip angle (FA)=30°, phase cycles (PC)=4, averages=3, 
resolution=200x200x200µm3.  For 19F imaging the parameters were: TR=5.5ms, 
TE=2.8ms, rBW=25kHz, FA=70°, PC=4 averages=30, resolution=0.5x0.5x1mm3. 
Imaging parameters were chosen based upon optimization work performed in previous 
studies27,28. Total protocol time for both 1H and 19F imaging was under 60 minutes.   
Mice were imaged immediately following hMSC implantation (day 0) and on days 2, 6, 
10, and 14. During scanning the mice were anesthetized with 2% isoflurane in 100% 
oxygen, with breathing rate and temperature monitored. A 1ms Gaussian shaped 
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excitation pulse was used to prevent detection of 19F signal from the isoflurane anesthetic, 
as described in more detail previously27. 
4.2.4 Image Analysis and Quantification 
Prior to image analysis a signal correction was applied to the 19F datasets by subtracting 
the value of the voxel containing the lowest signal in the dataset using ImageJ 
software41,42. 19F signal quantification was performed using Voxel TrackerTM software. 
The total signal contained within a hand drawn ROI produced by the 19F labeled cells was 
compared to the average signal produced by the reference tube of known concentration 
(3.33x1016 19F spins/µL). This information was used alongside Fc measured with NMR, 
to quantify the apparent number of cells located at the ROI, as described by Srinivas et 
al43. Significance between time-points was assessed using a repeated measures, one-way 
ANOVA using GraphPad Prism 6 software (GraphPad, San Diego, CA, USA).  
4.2.5 Immunohistochemistry 
Mice were sacrificed and perfusion fixed with 4% paraformaldehyde (PFA) following the 
final imaging timepoint on day 14. In addition, two mice from group A and B were 
sacrificed and perfused; 24 hours following i.v. iron injection (day 2) for comparison. 
Tissue was cryoprotected with increasing concentrations of sucrose (10%, 20%, 30%) 
before freezing in OCT medium, and sectioned at 12µm thickness. A DAB-enhanced 
Prussian Blue stain was used to detect iron. Prussian Blue staining was performed with 
the slides were placed in 4% potassium ferrocyanide (Fisher Scientific, Waltham, MA) 
and 4% hydrochloric acid.  After washing, DAB- intensification was performed 3,3’-
diaminobenzidine tetrahydrochloride (DAB; Sigma Aldrich, St Louis, MO) staining.  
Lectin immunofluorescence was then performed on the iron-stained sections to identify 
macrophages. First, sections were incubated with biotinylated isolectin B4 (Sigma 
Aldrich) and Triton X-100 overnight. Sections were then incubated in the dark with 
streptavidin conjugated with fluor 488 (1:500; ThermoFisher Scientific). Finally, tissue 
was counterstained with Hoechst stain for detection of cell nuclei. Fluorescence 
microscopy was performed to image the red fluorescent 19F-label as well as the green 
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fluorescent lectin label with a Zeiss AXIO Imager microscope (Carl Zeiss Canada Ltd). 
Slides were assessed through visual inspection. 
4.3 Results 
hMSC labeling with 19F 
NMR revealed the cellular loading, Fc, varied between study replications within the range 
of 8.2x1010 to 2.4x1011 19F atoms/cell. This large variability in labeling efficiency 
between replications has been previously observed in numerous studies with human 
cells28,44. Previous work by our group demonstrated that labeling hMSC with Cell Sense, 
does not negatively impact viability or differentiation into osteogenic or adipogenic 
lineages27,28.  
In vivo detection of 19F-labeled hMSC 
On the day of implantation (day 0) the 19F-labeled hMSC were visible in all mice in 
Groups A and B (Figure 18). In Group A, the mice that received only 19F labeled hMSC, 
the 19F signal gradually decreased between days 0 and 14 post implantation (Figure 18A-
E). This result is expected as the implanted hMSC die, and the 19F label is dispersed. At 
the endpoint, the average 19F signal was 22±11% of the initial value. One mouse within 
this group had no detectable signal in the final imaging session.  
In Group B, the mice that received i.v. Feraheme 24 hours after the hMSC implantation, a 
large region of signal void was visible at the implant site in day 2 proton images (Figure 
18G, day 2). Coincident with this was a significant decrease in the detected 19F signal 
compared to the day 0 signal from the same group. This is due to quenching of the 19F 
signal by the spin dephasing produced by nearby iron nanoparticles. Between days 2 and 
14 the 19F signal remained lower in Group B for each time point compared to Group A 
and the region of signal void persisted in the proton images. Signal loss was also 
observed in the lymph nodes, spleen and liver following i.v. Feraheme administration, 
resulting from the uptake of iron nanoparticles by macrophages of the reticuloendothelial 
system. 
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Figure 18: 
Representative images 
at each time point 
from Group A and B.  
Images were produced 
by overlaying 19F 
signal onto proton 
images for anatomical 
context. Mice were 
imaged over 14 days 
following 
intramuscular 
injection of 19F agent 
labeled hMSC on Day 
0 (A,F). Detected 19F 
signal from the hMSC 
implant is denoted by 
a yellow arrow in each 
image. Quantification 
of the apparent 
number of hMSC from 19F signal was calculated using reference tubes of known 19F 
concentration.  The reference tube is visible in panels I & J, and partially visible in 
panel F. Mice in group A (A-E), received no further treatment besides imaging. 
Group B mice (F-J) received i.v. iron on Day 1 following fluorine-labelled stem cell 
transplant.  The i.v. iron is taken up by macrophages and monocytes in the 
bloodstream.  On Day 2 (G), a large region of signal void is visible at the implant 
site. The presence of signal void indicates iron labeled immune cells have migrated 
to the implant site. This signal void region persists at each time point until endpoint 
on day 14 (G-J). No signal loss was observed in the muscle of the untreated leg. In 
addition to the implant site; voids were also visible in the lymph nodes, lymphatics, 
liver, and spleen. 
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Quantification of the 19F signal for Groups A and B is shown in Figure 19. For both 
Groups A and B we present the apparent number of hMSC, determined as described in 
the methodology. On day 0 the mean values for cell number were 0.99±0.08 x106 and 
1.08±0.08 x106 for Groups A and B, which agree strongly with the number of cells 
implanted (i.e., 1x106 cells). In Group A, the apparent cell number decreased between 
days 0 and 14 post implantation. Significant differences in the mean apparent cell number 
were observed between days 0 and 6, days 2 and 10, and days 6 and 14.  This 
quantification indicates that over time the 19F labeled hMSC diminish in number, most 
likely due to cell death and clearance. 
 
Figure 19: Quantification of 19F signal at each time point. Significance between 
groups A&B at the same time point is donated with (#).  Within the same group, 
over time is donated (†) between the previous time point and (‡) for between two 
time points. On day 0, both group A and B signal is in strong agreement with each 
other and with the expected number of implanted hMSC (1x106). Overtime, in 
group A 19F signal decreased at each subsequent time point.  This is likely due to cell 
death and 19F agent clearance by the immune system. In group B, following i.v. iron 
administration there is a significant decrease in 19F signal (day 2) compared to the 
previous time point and the Group A mice at the same time point.  After this there is 
no significant change in 19F signal in group B at any other time point. 
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For Group B, the mean apparent cell number sharply declined between days 0 and 2. This 
significant decrease reflects the presence of iron-positive macrophages, which has 
quenched the 19F signal from the labeled hMSC45. Between days 2 and 14 there was no 
significant change in apparent cell number, suggesting that the iron-labeled macrophages 
persist at the implant site. When comparing between Groups A and B a significant signal 
difference was observed on days 2 and 6.   Control mice, which received HBSS instead of 
hMSC, followed by i.v. Feraheme (Group C), did not have any signal voids within the 
muscle at any time point (Figure 20). For Group D mice, which received unlabeled 
hMSC on day 0 and i.v. 19F agent on day 1, the 19F signal was detected at the site of the 
cell implant in images acquired on day 2 and did not change significantly for the duration 
of the experiment (Figure 21).  
 
Figure 20: A sham model of Group B was produced by performing an 
intramuscular injection containing only saline on day 0, followed by intravenous 
iron on day 1. On day 2, no proton signal voids were detectable within the muscle. 
Signal voids were detectable within the bone marrow, lymph nodes, and liver, 
indicating the iron injection was successful. These regions are marked by white 
arrows. 
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Figure 21: Inflammation was assessed by performing an intramuscular injection 
containing unlabeled hMSC on day 0, followed by i.v. 19F agent on day 1 [Group D]. 
A representative 19F/1H overlaid image from day 2 shows a similar inflammation 
pattern within the muscle [white arrow] as observed with iron oxide (A). On day 2 a 
mean of 2.5±1.3x1018 19F spins was detected at the transplant site. 19F signal was also 
detected at the lymph node [yellow arrow].  Unlike Group B, the 19F-labeled 
macrophages can be quantified over time (B). The relative signal normalized to day 
2 within each mouse provides a measure of change in inflammation over time.  No 
significant differences were observed at any time point. 
Microscopy and Immunohistochemistry  
Macrophages in the muscle tissue were identified through low magnification (10x) 
fluorescence microscopy of lectin immunohistochemistry-stained sections (Fig 22A&E). 
In mice euthanized on day 2, macrophages were localized within and surrounding the site 
of hMSC implantation, which was visible by the red fluorescence associated with the 19F 
agent (Fig 22B). An overlay of the green, red, and blue (Hoescht) images revealed that 
there were macrophages within the hMSC tract that appear to be associated with the 19F 
agent and other macrophages which were not. This is evident in the inset of Figure 22D 
where yellow suggests the co-localization of the fluorescence from the green 
macrophages and red 19F agent. In mice euthanized on day 14, macrophages distribution 
appeared different compared to day 2 with green fluorescent signal predominately visible 
within the stem cell tract (Fig 22E). This was coincident with a visible decrease in the 
area of red fluorescence (Fig 22B), which agreed with the finding of decreased
    
 
Figure 22: Fluorescence microscopy showing the intramuscular injection track on day 2 (A-D) and day 14 (E-H).  
Macrophages were stained with a green fluorescent lectin+ marker.  At the early time point on day 2, macrophages are visible 
both within and surrounding the stem cell track (A).  By endpoint on day 14, macrophages are only found within the 
transplant track (E). Scale bars denote 300 µm.  The red fluorescent 19F agent is visible within the stem cell track from the 
same tissue sections.  More red fluorescence is visible on day 2 (B) then on day 14 (F), in agreement with MRI signal.  Cell 
nuclei were detected with blue Hoeschst staining (C,G). Merged fluorescent images show some bystander labeling of 
macrophages, appearing as yellow.  On day 2, there are few bystander labeled macrophages, as indicated by the separation 
between red and green fluorescent markers (H). However, by day 14 the majority of 19F agent is contained within 
macrophages (H). This is highlighted within the magnified inset in the lower left corner (width 150µm). 
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19F signal by MRI.  The overlay (Fig 22H) suggests that 14 days after hMSC implantation 
the majority of the macrophages are restricted to the implant site, and are co-localized 
with the 19F-labeled hMSC.  
Tissue sections for mice in Group B are shown in Figure 23, alongside a representative 
proton image obtained on day 2. A large region of signal loss is visible in the muscle 
tissue (arrow).  Iron stained cells appear dark brown within the muscle tissue sections on 
both day 2 (Fig 23B) and day 14 (Fig 23D).  More iron-labeled cells were detected at day 
14 compared to day 2. The corresponding red fluorescence images of these sections (Fig 
23C&E) show the 19F agent and the stem cell tract.  The iron was often colocalized with 
the 19F signal, especially at day 14, suggesting that macrophages have taken up dead 19F 
labeled hMSC and have become co-labeled with iron and 19F. 
 
Figure 23: Signal void is visible in the axial proton images of the muscle after stem 
cell transplant on day 2 (A).  The transplant site is denoted by the white arrow. No 
signal void is visible in the opposite, untreated, hindlimb muscle.  Histology reveals 
the presence of iron within the muscle tissue on both day 2 (B) and day 14 (D).  Scale 
bars denote 300µm. The accompanying stem cell track is outlined by the red 
fluorescent 19F agent (C,E). More iron is found within the stem cell track at 
endpoint compared to day 2; often colocalized with the 19F agent. suggesting it is 
contained within bystander labeled immune cells. 
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4.4 Discussion 
In this study, the use of two different cellular MRI agents for tracking distinct cell 
populations was investigated. Pre-labeling of hMSC with a 19F-agent provided specific 
and quantifiable information through the direct detection of the 19F spins. Intravenous 
administration of USPIO allowed for the in vivo detection of hMSC rejection through the 
tracking of infiltrating of iron-labeled macrophages which were visualized in proton 
images as signal loss, and which impacted the 19F signal from hMSC through 19F signal 
quenching.   
In agreement with previous studies27, we have shown an excellent correlation between 
the number of transplanted cells and the 19F-MRI quantification on day 0 following pre-
labeling of stem cells with 19F.  This highlights an advantage of 19F-MRI, that cellular 
delivery to the target can be confirmed through localization and quantification of 19F-
labeled stem cells soon after transplant.  In a previous study, stem cell survival and label 
retention was demonstrated immediately following transplantation into a murine host27. 
The change in 19F-signal over time also provides longitudinal information on the status of 
therapy. A reduction in 19F-signal at the injection site suggests stem cells are either 
migrating away from, or dying, at the therapeutic site. Due to the immune competent 
xenograft model investigated, this decrease is likely predominately due to stem cell death 
and label clearance, as opposed to stem cell migration away from the injection tract46. As 
transplanted cells die the 19F signal will be reduced as the label is cleared from the local 
tissue. In this study, a decrease in 19F signal was observed for all Group A mice by MRI 
and fluorescence microscopy over the 14 days. Microscopy and immunohistochemistry 
indicated that macrophages are present at the transplant site in Group A mice as early as 
day 2 and that the majority are 19F positive at the endpoint on day 14, in a process known 
as bystander labeling. The steady decrease in 19F signal over time measured by MRI in 
Group A suggests that 19F labeled macrophages must be leaving the site.  By day 14 since 
most macrophages are 19F positive, stem cell survival at our endpoint is being 
overestimated by 19F MRI.  
In Group B, the observation of signal voids in proton images in the muscle after i.v. 
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USPIO is consistent with the infiltration and accumulation of iron-labeled macrophages. 
Previous studies which used i.v. USPIO have shown similar results, and have suggested 
that imaging macrophages this way could be used as an early indication of transplant 
rejection30. In our study, coincident with the detection of signal loss in proton images was 
a significant decrease in 19F-MRI signal from the stem cells. This is the result of 
quenching of the 19F signal by USPIO-labeled cells.  After the large reduction in the 19F 
signal on day 2, post i.v. USPIO, the 19F signal did not change any further (day 2 to day 
14). This observation differed from the steady signal decline observed within Group A, 
and is likely due to the inability to accurately quantify 19F signal following the influx of 
iron oxide to the site of transplant.  In the presence of iron oxide, the 19F signal is not 
linearly related to the concentration of 19F spins and localized changes in relaxation rates 
render signal comparison to the external 19F reference tube invalid. Longitudinal changes 
in 19F signal are further complicated due to the saturation of signal quenching in the 
presence of large quantities of iron oxide, which may mask changes in iron-labeled cells 
over time3. Nevertheless, the significant effect on 19F signal is advantageous in rapidly 
detecting the onset of acute inflammation.  
Quenching of 19F signal was first reported in a study by Hitchens et al. that explored the 
quenching of signal when 19F-labeled cells are co-labeled with iron nanoparticles45.  They 
showed that the 19F T2 was significantly reduced in cells that were labeled with both iron 
and 19F, but that iron-labeled cells mixed equally with 19F-labeled cells did not impact the 
19F T2.  To test the feasibility of detecting different 19F labeled cells in vivo they used a 
mouse inflammation model where 19F and/or USPIO was injected i.v. to label 
macrophages.  Mice were either administered both the 19F agent and USPIO i.v. at the 
same time or the 19F agent one day and USPIO the next day to try to generate co-labeled 
or co-localized cell populations.  More 19F signal quenching was observed when both 
agents were administered simultaneously (co-labeled). Quenching was also observed for 
co-localized cells in gradient echo Fast Low Angle SHot (FLASH) images, but not in 
spin echo Rapid Acquisition with Relaxation Enhancement (RARE) images45. These 
important observations set the stage for the work we present here in a mouse model of 
stem cell transplantation and rejection.  
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Our in vivo results and supportive microscopy suggests that iron-labeled cells nearby 19F-
labeled cells (co-localized), and cells which are co-labeled with iron and 19F, both cause 
quenching of the 19F signal with our bSSFP imaging protocol. The bSSFP sequence is a 
rapid gradient echo imaging method with balanced gradient waveforms, which 
establishes a unique steady state47. bSSFP has features of both gradient and spin echo 
sequences and image contrast that is predominately related to T2/T1, but can be a 
combination with spin-density under some imaging conditions48. Our observation of 
signal quenching may also be due to the differences in spatial proximity and iron 
concentration present in vivo due to the infiltration of immune cells. Since MRI signal 
loss is only linearly related to iron oxide concentration at very low concentrations, the 
influx of additional iron oxide over time may not lead to a further decrease in signal3.  
Future work is required to better understand signal quenching with bSSFP and to 
determine if there is a minimum distance required to distinguish co-localized from co-
labeled cells.   
4.5 Conclusions 
In summary, this study investigated the use of two cellular MRI approaches to track 
distinct cell types.  Stem cells were pre-labeled and directly detected and quantified with 
19F-MRI over time and macrophages were labeled in situ using iron oxide nanoparticles 
and imaged with proton MRI to detect the infiltration of immune cells at the transplant 
site. To the best of our knowledge this is the first study that has used both proton and 19F 
MRI to track two different cell types in vivo with multiple cellular MRI mechanisms. 
By combining these well studied MRI cell tracking methodologies, it is possible to non-
invasively verify both treatment delivery with 19F-MRI and to monitor transplant 
rejection status with iron nanoparticles.  Ultimately, through this technique it may be 
possible to obtain additional information on the rejection process and on the ultimate fate 
of transplanted stem cells.   
4.6 References 
1. Shapiro EM, Sharer K, Skrtic S, Koretsky AP. In vivo detection of single cells by 
  
83 
MRI. Magnetic Resonance in Medicine. 2006;55(2):242–9. 
2. Heyn C, Ronald J a, Mackenzie LT, MacDonald IC, Chambers AF, Rutt BK, Foster 
PJ. In vivo magnetic resonance imaging of single cells in mouse brain with optical 
validation. Magnetic Resonance in Medicine. 2006;55(1):23–9. 
3. Heyn C, Bowen C V, Rutt BK, Foster PJ. Detection threshold of single SPIO-labeled 
cells with FIESTA. Magnetic Resonance in Medicine. 2005;53(2):312–20. 
4. Fox MS, Gaudet JM, Foster PJ. Fluorine-19 MRI Contrast Agents for Cell Tracking 
and Lung Imaging. 2015;8:1–15. 
5. Bulte JWM, Walczak P, Janowski M, Krishnan KM, Arami H, Halkola A, Gleich B, 
Rahmer J. Quantitative “Hot Spot” Imaging of Transplanted Stem cells using 
Superparamagnetic Tracers and Magnetic Particle Imaging (MPI). Tomography. 
2015;8(12):1699–1712. 
6. Nejadnik H, Castillo R, Daldrup-Link HE. Magnetic Resonance Imaging and Tracking 
of Stem Cells. Methods in Molecular Biology. 2013;1(1052):167–176. 
7. Xu C, Miranda-Nieves D, Ankrum J a, Matthiesen ME, Phillips J a, Roes I, 
Wojtkiewicz GR, Juneja V, Kultima JR, Zhao W, et al. Tracking mesenchymal 
stem cells with iron oxide nanoparticle loaded poly(lactide-co-glycolide) 
microparticles. Nano letters. 2012;12(8):4131–9. 
8. Gonzalez-Lara LE, Xu X, Hofstetrova K, Pniak A, Chen Y, McFadden CD, Martinez-
Santiesteban FM, Rutt BK, Brown A, Foster PJ. The use of cellular magnetic 
resonance imaging to track the fate of iron-labeled multipotent stromal cells after 
direct transplantation in a mouse model of spinal cord injury. Molecular Imaging 
and Biology. 2011;13(4):702–11. 
9. Helfer BM, Balducci A, Sadeghi Z, O’Hanlon C, Hijaz A, Flask C a, Wesa AK. (19)F 
MRI tracer preserves in vitro and in vivo properties of hematopoietic stem cells. 
Cell transplantation. 2013;22(1):87–97. 
10. Partlow KC, Chen J, Brant J a, Neubauer AM, Meyerrose TE, Creer MH, Nolta J a, 
Caruthers SD, Lanza GM, Wickline S a. 19F magnetic resonance imaging for 
stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. 
  
84 
The FASEB Journal. 2007;21(8):1647–54. 
11. Psaltis P, Zannettino A. Concise review: mesenchymal stromal cells: potential for 
cardiovascular repair. Stem Cells. 2008:2201–2210. 
12. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell. 
2012;10(6):709–16. 
13. Segers VFM, Lee RT. Stem-cell therapy for cardiac disease. Nature. 
2008;451(7181):937–42. 
14. Boehm-Sturm P, Aswendt M, Minassian A, Michalk S, Mengler L, Adamczak J, 
Mezzanotte L, Löwik C, Hoehn M. A multi-modality platform to image stem cell 
graft survival in the naïve and stroke-damaged mouse brain. Biomaterials. 
2014;35(7):2218–26. 
15. Khabbal J, Kerkelä E, Mitkari B, Raki M, Nystedt J, Mikkonen V, Bergström K, 
Laitinen S, Korhonen M, Jolkkonen J. Differential Clearance of Rat and Human 
Bone Marrow-Derived Mesenchymal Stem Cells from the Brain After Intra-
arterial Infusion in Rats. Cell transplantation. 2014 Mar 3. 
16. Murphy SP, Porrett PM, Turka L a. Innate immunity in transplant tolerance and 
rejection. Immunological reviews. 2011;241(1):39–48. 
17. Reagan MR, Kaplan DL. Concise review: Mesenchymal stem cell tumor-homing: 
detection methods in disease model systems. Stem cells (Dayton, Ohio). 
2011;29(6):920–7. 
18. Lauber K, Blumenthal SG, Waibel M, Wesselborg S. Clearance of Apoptotic Cells : 
Getting Rid of the Corpses The efficient elimination of apoptotic cells is crucial. 
Molecular Cell. 2004;14:277–287. 
19. Wyburn KR, Jose MD, Wu H, Atkins RC, Chadban SJ. The Role of Macrophages in 
Allograft Rejection. Transplantation. 2005;80(12):1641–1647. 
20. Auchincloss H, Sachs DH. Xenogeneic transplantation. Annual review of 
immunology. 1998;16:433–470. 
21. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 
  
85 
2006;124(4):783–801. 
22. Noad J, Gonzalez-Lara LE, Broughton HC, McFadden C, Chen Y, Hess D a, Foster 
PJ. MRI tracking of transplanted iron-labeled mesenchymal stromal cells in an 
immune-compromised mouse model of critical limb ischemia. NMR in 
Biomedicine. 2013;26(4):458–67. 
23. Amsalem Y, Mardor Y, Feinberg MS, Landa N, Miller L, Daniels D, Ocherashvilli A, 
Holbova R, Yosef O, Barbash IM, et al. Iron-oxide labeling and outcome of 
transplanted mesenchymal stem cells in the infarcted myocardium. Circulation. 
2007;116(11 SUPPL. 1):38–46. 
24. Terrovitis J, Stuber M, Youssef A, Preece S, Leppo M, Kizana E, Schär M, 
Gerstenblith G, Weiss RG, Marbán E, et al. Magnetic resonance imaging 
overestimates ferumoxide-labeled stem cell survival after transplantation in the 
heart. Circulation. 2008;117(12):1555–62. 
25. Berman SC, Galpoththawela C, Gilad AA, Bulte JWM, Walczak P. Long-term MR 
cell tracking of neural stem cells grafted in immunocompetent versus 
immunodeficient mice reveals distinct differences in contrast between live and 
dead cells. Magnetic Resonance in Medicine. 2011;65(2):564–574. 
26. Bernau K, Lewis CM, Petelinsek AM, Reagan MS, Niles DJ, Mattis VB, Meyerand 
ME, Suzuki M, Svendsen CN. In Vivo Tracking of Human Neural Progenitor 
Cells in the Rat Brain Using Magnetic Resonance Imaging is Not Enhanced by 
Ferritin Expression. Cell Transplantation. 2015;25:575–592. 
27. Gaudet JM, Ribot EJ, Chen Y, Gilbert KM, Foster PJ. Tracking the Fate of Stem Cell 
Implants with Fluorine-19 MRI. Plos One. 2015;10:e0118544. 
28. Ribot EJ, Gaudet JM, Chen Y, Gilbert KM, Foster PJ. In vivo MR detection of 
fluorine-labeled human MSC using the bSSFP sequence. International Journal of 
Nanomedicine. 2014;9:1731–9. 
29. Zhang Y, Dodd SJ, Hendrich KS, Williams M, Ho C. Magnetic resonance imaging 
detection of rat renal transplant rejection by monitoring macrophage infiltration. 
Kidney International. 2000;58(3):1300–1310. 
  
86 
30. Khurana  a., Nejadnik H, Gawande R, Lin G, Lee S, Messing S, Castaneda R, 
Derugin N, Pisani L, Lue TF, et al. Intravenous Ferumoxytol Allows Noninvasive 
MR Imaging Monitoring of Macrophage Migration into Stem Cell Transplants. 
Radiology. 2012;264(3):803–811. 
31. Wu Y, Ye Q, Eytan DF, Liu L, Rosario BL, Hitchens TK, Yeh F-C, van Rooijen N, 
Ho C. MRI Investigation of Macrophjages in acute cardiac allograft rejection after 
heart transplantation. Circulation: Cardiovascular Imaging. 2011;72(2):181–204. 
32. Kanno S, Wu YJ, Lee PC, Dodd SJ, Williams M, Griffith BP, Ho C. Macrophage 
accumulation associated with rat cardiac allograft rejection detected by magnetic 
resonance imaging with ultrasmall superparamagnetic iron oxide particles. 
Circulation. 2001;104(8):934–938. 
33. Iv M, Telischak N, Feng D, Holdsworth S., Yeom K., Daldrup-Link H. Clinical 
applications of iron oxide nanoparticles for magnetic resonance imaging of brain 
tumors. Nanomedicine (Lond). 2015;10(6):993–1018. 
34. Vasanawala SS, Nguyen K-L, Hope MD, Bridges MD, Hope TA, Reeder SB, Bashir 
MR. Safety and technique of ferumoxytol administration for MRI. Magnetic 
Resonance in Medicine. 2016;75(5):2107–2111. 
35. Hitchens TK, Ye Q, Eytan DF, Janjic JM, Ahrens ET, Ho C. 19F MRI detection of 
acute allograft rejection with in vivo perfluorocarbon labeling of immune cells. 
Magnetic resonance in medicine. 2011;65(4):1144–53. 
36. Ahrens ET, Young W, Xu H, Pusateri LK. Reports Rapid quantification of 
inflammation in tissue samples using perfluorocarbon emulsion and fluorine-19 
nuclear magnetic resonance. BioTechniques Focus:Translational Tools. 
2011:229–234. 
37. Weise G, Basse-Luesebrink TC, Wessig C, Jakob PM, Stoll G. In vivo imaging of 
inflammation in the peripheral nervous system by (19)F MRI. Experimental 
neurology. 2011;229(2):494–501. 
38. Jacoby C, Temme S, Mayenfels F, Benoit N, Krafft MP, Schubert R, Schrader J, 
Flögel U. Probing different perfluorocarbons for in vivo inflammation imaging by 
  
87 
(19) F MRI: image reconstruction, biological half-lives and sensitivity. NMR in 
Biomedicine. 2014;27(3):261–71. 
39. Dayan V, Yannarelli G, Billia F, Filomeno P, Wang X-H, Davies JE, Keating A. 
Mesenchymal stromal cells mediate a switch to alternatively activated 
monocytes/macrophages after acute myocardial infarction. Basic research in 
cardiology. 2011;106(6):1299–310. 
40. Helfer BBM, Balducci A, Nelson AD, Janjic JM, Gil RR, Kalinski P, Vries IJMDE, 
Ahrens ET, Mailliard RB, de Vries IJM. Functional assessment of human 
dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking. 
Cytotherapy. 2010;12(2):238–50. 
41. Abràmoff MD, Magalhães PJ, Ram SJ. Image processing with imageJ. Biophotonics 
International. 2004;11(7):36–41. 
42. Schneider C a, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image 
analysis. Nature Methods. 2012;9(7):671–675. 
43. Srinivas M, Morel PA, Ernst L a, Laidlaw DH, Ahrens ET. Fluorine-19 MRI for 
visualization and quantification of cell migration in a diabetes model. Magnetic 
Resonance in Medicine. 2007;58(4):725–34. 
44. Boehm-Sturm P, Mengler L, Wecker S, Hoehn M, Kallur T. In Vivo Tracking of 
Human Neural Stem Cells with 19F Magnetic Resonance Imaging. PloS ONE. 
2011;6(12):e29040. 
45. Hitchens TK, Liu L, Foley LM, Simplaceanu V, Ahrens ET, Ho C. Combining 
Perfluorocarbon and Superparamagnetic Iron-Oxide Cell Labeling for Improved 
and Expanded Applications of Cellular MRI. Magnetic Resonance in Medicine. 
2015;73(1):367–375. 
46. Eggenhofer E, Luk F, Dahlke MH, Hoogduijn MJ. The life and fate of mesenchymal 
stem cells. Frontiers in Immunology. 2014;5(MAY):1–6. 
47. Scheffler K, Lehnhardt S. Principles and applications of balanced SSFP techniques. 
European Radiology. 2003;13(11):2409–18. 
48. Huang TY, Huang IJ, Chen CY, Scheffler K, Chung HW, Cheng HC. Are trueFISP 
  
88 
images T2/T1-weighted? Magnetic Resonance in Medicine. 2002;48(4):684–688. 
 
 
  
89 
Chapter 5  
5 Translation of High-field Fluorine-19 Cell Tracking into 
the Clinical Realm 
5.1 Introduction 
Application of non-invasive, non-toxic, in vivo imaging is essential to the future of 
improving cellular therapy. By developing cellular MRI, it might one day be possible to 
rapidly determine if a patient will respond to treatment through diagnostic imaging, 
without waiting for symptomatic signs. Clinical trial outcomes could be improved by 
separating non-responders from those with an unsuccessful cell injection.   
The first clinical application of MRI cell tracking was in verifying DC administration for 
melanoma immunotherapy1.  Dendritic cells are ideally suited for cell tracking translation 
due to their clinical relevance and reliance on migration to the lymph node.  In 2005, de 
Vries et al. tracked mixed SPIO- and 111In-labeled DC injected intranodally under 
ultrasound guidance.1 In this study, MRI was found to be at least as sensitive as 
scintigraphic images, with significant improvements in spatial localization. MRI also 
showed that a large percentage of guided injections had missed their target injection site, 
highlighting the application of cellular MRI in verifying treatment delivery. Since 2005, 
iron-based cellular MRI has been used clinically to track a variety of cell types, in 
addition to dendritic cells,2 such as: neural stem cells,3,4 hematopoietic stem cells,5 and 
pancreatic islet grafts.6  Yet despite the large potential, wide-spread clinical use of iron 
oxide based cellular MRI has not been achieved.  This is largely due to the unavailability 
of a commercial, FDA approved imaging agent.  In 2008, Feridex™ an iron-based MRI 
reticuloendothelial system contrast agent, was taken off market.  Up until this point 
Feridex had been used off-label in the majority of cell tracking trials.  
In 2014, the first 19F-MRI clinical cell tracking trial was performed using a commercial 
perfluorocarbon imaging agent, Cell Sense, to track the administration of DC in patients 
with colorectal cancer.7 Dr. Ahrens’ group observed an average of 3.9x1012 19F/cell, with 
no decrease in cell viability or changes to phenotype.  A Fast Low Angle SHot (FLASH) 
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imaging sequence was used on a Siemens 3T clinical MRI system with a 19F-scan time of 
9.5 minutes. Patients received either a low dose (1x106 DC, N=2) or a high dose (1x107 
DC, N=3) and imaging was performed twice, 4 and 24 hours after administration. 19F 
signal was only detected at the injection site in high dosage patients. Quantification of 
signal at the injection site showed that the 19F-MRI signal decreased by approximately 
50% between the two imaging time points.  This suggested that DC migrated from the 
initial site. However, no signal was observed in the nearby lymph nodes, likely due to the 
limited sensitivity. Recently a 19F clinical protocol for imaging Stromal Vascular Fraction 
(SVF) cells was published.8  With applications in breast reconstruction, the SVF is 
comprised of a heterogeneous mixture of cells, with a large percentage of adipose derived 
stem cells.  Extensive work was performed to show no phenotypic changes from labeling. 
Preferential 19F uptake was observed within some cells, with an average overall cellular 
loading of 2.8±2x1012 19F/cell. Dr. Bulte’s group was able to show a detection limit of 
2x106 SVF cells implanted 5mm below the surface of the phantom, however no signal 
was observed from a similar injection 1cm deep.  
In this study, we sought to develop the first clinical 19F-cell tracking imaging protocol in 
Canada for imaging peripheral blood mononuclear cells (PBMC).  Used in the first FDA 
approved anticancer vaccine, sipuleucel-T cell therapy targets castration resistant prostate 
cancer. Autologous PBMC are collected and incubated with a fusion protein containing 
prostatic acid phosphatase (PAP) antigen linked to granulocyte-macrophage colony-
stimulating factor (GM-CSF), prior to administration back into the patient.9  Success of 
therapy relies on the migration of these PBMC to secondary lymphoid organs such as the 
inguinal lymph nodes in the upper thigh.10  In this work we present an imaging pipeline 
allowing for treatment to be first developed and optimized in pre-clinical models, then 
translated to a clinical protocol.  Migration of 19F-labeled PBMC to the draining lymph 
node was demonstrated in mice to show that treatment could be developed and optimized 
in high throughput pre-clinical models.  PBMC were imaged with a clinical protocol 
following injection into a ham shank phantom to simulate the human thigh. 
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5.2 Methods 
5.2.1 Labeling of PBMC with Cell Sense 
Blood from C57Bl/6 mice was collected by venous puncture, according to animal use 
protocols approved by Western University Animal Use Committee.  Human peripheral 
blood mononuclear cells (hPBMCs) were collected from two healthy volunteers who had 
consented to a protocol approved by the University of Western Ontario Research Ethics 
Board (London, ON, Canada). Approximately 100 - 160 mL of blood was drawn 
following hospital procedure. In both cases, PBMCs were isolated from the blood using 
gradient centrifugation via a Ficoll overlay. PBMC were washed in HBSS and re-
suspended in AIM-V® Medium CTS at 5x106 cells/mL in 1 well of a 12 well plate 
(Falcon, Mississauga, Canada). Cells were labeled with 5mg/mL of Cell Sense (CS-
1000), overnight prior to administration.  Following labeling, an aliquot of cells was set 
aside in each experimental repetition of determination of intracellular 19F content. 
5.2.2 Pre-clinical MRI of PBMC Migration 
Male nu/nu mice (8-10 weeks) (n=20) were purchased from Charles River Laboratories 
Inc. (Saint Constant, Canada) and housed at Robarts Research Institute at Western 
University (London, Canada) in a pathogen-free barrier facility. Animal use guidelines 
were followed for all experiments conducted and pre-approved by the Animal Use 
Subcommittee at Western University. In each mouse, the right lymph node was pre-
treated with the pro-inflammatory agent IL-1b prior to PBMC administration. This agent 
is expected to increase lymphatic drainage to the node, potential promoting the number of 
PBMC which arrive. 5-6x106 19F-labeled mPBMC were injected into each of the right 
and left footpads, 48 hours prior to imaging. In 10 animals, mPBMC were matured with 
GM-CSF, prior to administration but after 19F-labeling. By maturing the PBMC, they are 
more likely to migrate to the draining lymph node and stimulate the immune system.  
This produced four treatment models in the mice; 1) Untreated PMBC, 2) GM-CSF+ 
matured PBMC, 3) IL-1b treated lymph nodes, and 4) GM-CSF+ PBMC & IL-1b treated 
LN. The frequency of signal detection and quantity of migrating cells to the lymph node 
were compared between the four treatments. 
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Murine imaging was performed with a 9.4T Varian small-animal MRI scanner. A 3D-
balanced steady state free precession (bSSFP) sequence was used for both 1H and 19F 
imaging. Animals were imaged alongside an agarose diluted Cell Sense reference tube of 
known 19F concentration (3.33x1016 19F/µL). Mice were anesthetized with 2% isoflurane, 
with breathing rate and temperature monitored throughout the scan. MRI was performed 
using a dual-tuned birdcage volume coil (diameter 2.2cm, length 5.1cm), tuned to 400.2 
MHz and 376.8 MHz for 1H and 19F imaging respectively.  For 1H imaging the scan 
parameters were: repetition time (TR)=5.0ms, echo time (TE)=2.5ms, receiver bandwidth 
(rBW)=78kHz, flip angle (FA)=30°, phase cycles (PC)=4, averages=3, 
resolution=200x200x200µm3.  For 19F imaging the parameters were: TR=4.0ms, 
TE=1.9ms, rBW=25kHz, FA=70°, PC=4, averages=250, resolution=1x1x1mm3. Total 
protocol time for both 1H and 19F imaging was under 90 minutes.   
5.2.3 Clinical MRI Protocol 
Samples were imaged with a GE MR750, 3 Tesla (T) MRI scanner equipped with a 
multinuclear pre-amplifier.  Imaging was performed with two dual 1H/19F-tuned 
switchable surface coils manufactured by Clinical MR solutions.  Detection sensitivity 
between a large coil (25.4cm x 17.8cm) was compared to a small coil (4.3cm x 4.3cm) 
with two arrays of trifluoroacetic acid (TFA) samples ranging from 0.0001%-1% with a 
volume of 1mL and 15mL. Based on these results, the small coil was used for all further 
experiments. Image acquisition was further optimized with hPBMC cell pellets 
containing 1-10x106 cells.  A 2D fast gradient echo (Fast GRE) sequence was used for 1H 
imaging with the following scan parameters: TE = 2.6ms, TR = 100ms, field of view 
(FOV) = 15cm x 15cm x 5cm, Image Matrix = 256x256, Slice thickness = 5mm, rBW = 
83kHz, and FA = 20°. Following 1H imaging, the coil was switched to 19F-mode and the 
same FOV was scanned. 19F images were obtained with a broad-banded 3D balanced 
Steady State Free Precession (bSSFP) based on the GE FIESTA-C sequence. The scan 
parameters were: TE= 2.2ms, TR= 4.4ms, FOV= 15cm x 15cm x 5cm, Image matrix = 
46x46, Slice thickness = 5mm, rBW= 10kHz, and FA= 70°. 19F imaging time was 15 
minutes, with a total protocol time under 30 minutes.  Clinical proof-of-concept imaging 
was performed with a ham shank phantom. PBMC from a healthy volunteer were labeled 
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with Cell Sense (5mg/mL) for 48 hours.  Realistic mock injections consisting of 1, 4.5, 
10.5, and 20 x106 PBMC were performed by injecting 19F-labeled cells into the ham 
shank at two depths.  A shallow intradermal injection was performed at approximately 
3mm depth along with a subcutaneous injection at 1cm depth. The study was repeated 
with PBMC from a second volunteer. 
5.2.4 Cellular Loading Efficiency and Signal Quantification 
The mean intracellular 19F content of the PBMC mixture was determined by Nuclear 
Magnetic Resonance (NMR) spectroscopy.  First, a known number of cells were fixed, 
then lysed through repeated cycles of sonication and freeze-thaw in solution containing 
100µL 5% Triton X-100.  After lysing, 300µL of D20 and 100µL of 0.1% TFA were 
added to the solution.  The TFA provides a reference peak for quantifying the number of 
19F spins/ cell, since NMR signal is linearly dependent on the number of 19F atoms 
present. 
For in vivo MRI signal quantification, the number of PBMC was determined with Voxel 
TrackerTM software.  Prior to analysis, a signal correction was applied to the 19F datasets 
by subtracting the signal value of the voxel containing the lowest signal in the dataset. 
Once the correction was applied, the total 19F-labeled cell signal contained within a hand-
drawn ROI was compared to the average signal produced by a reference tube of known 
concentration (3.33x1016 19F spins/µL). This information was used alongside the 19F/cell, 
measured with NMR, to quantify the apparent number of cells located at the ROI. 
5.3 Results 
Pre-clinical imaging of mPBMC 
For pre-clinical experiments either naïve PBMCs or GM-CSF exposed matured PBMCs 
were injected into the footpad.  In all cases 19F-signal was observed in both footpads of 
the mice. The number of detected mPBMC in the draining popliteal LN is outlined in 
Table 4.  When signal was detected, there was no significant difference in the number of 
migrating PBMC under any condition.  There is no difference in the frequency of 19F 
signal detection based on either cell maturation with GM-CSF (Table 4, column 1), node 
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pre-treatment with IL-1b (Table 4, column 2), or treatment with both GM-CSF and IL-1b 
(Table 4, column 3).  However, there was a significant difference in detection frequency 
when compared to the untreated controls (Table 4, column 4).   
Table 4: Summary of pre-clinical mPBMC migration to popliteal lymph nodes 
 
Imaging of hPBMC under clinical conditions  
Imaging translation was performed with a clinical-strength 3T GE MRI (Fig 24A), with a 
custom-designed 4.3cm dual-tuned 19F/1H surface coil (Fig 24B). Using the 7-channel 
GE body coil, human inguinal lymph nodes could be detected as dark spheres within the 
bright fat pad in the upper thigh (Fig 24C/D).  12 nodes were detected with an average 
volume of 390±290mm3 and an average depth of 1.5±0.3cm.  In a clinical trial, these 
high quality body coil images could be used to localize the target imaging area.  Prior to 
image optimization, the difference in detection sensitivity between the large and small 
coils was estimated with an array of TFA phantoms.  Here, the small surface coil 
displayed a higher sensitivity, by almost two orders of magnitude (Fig 25A). However, 
the effective imaging depth was significantly decreased, limiting the small coil to 
superficial imaging sites. 19F imaging parameters were optimized on the small coil using 
a series human PBMC cell pellet phantoms ranging from 1-10 x106 cells (Fig 25C). 
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Figure 24: MRI provides excellent soft tissue contrast and lymph node detection. 
Imaging protocol has been developed for a clinical 3T GE MRI (A). 19F imaging is 
performed with a small dual-tuned surface coil placed on the patients upper thigh, 
centered on the injection point (B).  A coronal orientation MRI with the body coil 
reveals the lymph nodes as dark spheres [blue arrow] within the fat of the upper 
thigh (C). The orange dashed line indicates the location of the axial MRI slice (D).  
In the axial image, the nodes were measured to be approximately 1.5cm below the 
skin (D). 
The pelleted cells were contained within individual Eppendorf tubes with 1% agarose 
poured on top to hold them in place.  Under optimum labeling conditions, with 4.2x1011 
19F/cell, as few as 1x106 PBMC could be detected (Fig 25D).   
As a proof-of-concept, human PBMC were administered into a ham shank prior to 
imaging with the dual-tuned surface coil (Fig 26).  The ham shank Human PBMC were 
19F-labeled (mean 1.2x1011 19F/cell) and administered intradermally in 4 doses: 1.5, 4.5, 
10.5 and 20 x106 cells (Fig 26A/B). With PBMC from the first donor, all injections were 
detectable and quantifiable with the exception of the lowest 1.5x106 PBMC dose.  In 
addition, a subcutaneous injection of 4.5x106 PBMC was placed below the intradermal 
dose.  This site was also visible 1.2cm below the surface (Fig 26B). The 19F/1H dual- 
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tuned coil was placed on the surface above the target location, as shown (Fig 26C). 1H 
images of the ham shank provided a realistic tissue model, as shown by the images of the 
human thigh with the same coil (Fig 26D).  
 
Figure 25: An array of phantoms containing 0.0001%-1% TFA in 1mL and 15mL 
tubes imaged with both the large and small surface coils (A).  In the sagittal proton 
image of this phantom, the blue arrows indicate tubes that were detectable with 
both coils, but only the small surface coil displayed sufficient sensitivity to detect 
those marked by the red arrows.  The lowest concentration detected, 0.001% 
represents the signal on the same order of magnitude of a million PBMC. Using the 
smaller coil did result in a significant increase in signal drop off with depth 
compared to the larger coil (B).  Cell pellet phantoms created by centrifuging 1x106, 
5x106 and 10x106 Cell Sense-labeled PBMC and overlaying with 1% agarose in an 
eppendorf tube (C). PBMC phantoms were placed on a saline bag and scanned at 
3T and all 3 phantoms described in (C) were detected using 19F cellular MRI (D), 
with a hot-iron colour scale used for 19F MRI.  
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Figure 26: Human PBMC can be detected under clinical conditions following 
injection into a ham shank. Cells were administered interdermally in 4 doses [yellow 
arrows], 20x106 (A), 10.5x106 (not shown), 4.5x106 (B) and 1.5x106. Only the smallest 
dose (1.5x106) was undetectable with our imaging parameters.  An additional 
4.5x106 dose was administered subcutaneously [blue arrow], which is visible at 
1.2cm depth as measured with MRI. Images were performed alongside a pair of 
reference tubes (R) of known 19F concentration allowing for signal quantification. 
The surface coil was placed directly on the ham shank, with the reference tubes 
taped inside the coil elements (C).  A representative human 1H image taken with the 
same parameters closely resembles the ham images in both tissue appearance and 
subcutaneous fat disposition (D). 
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When the experiment was repeated with PBMC from a different source labeling 
efficiency was observed to be much lower (4.2x1010 19F/cell).  A comparison of the 
20x106 PBMC dose is shown in Figure 27, where the images have been set to the same 
window and level. Under these conditions, only the 20x106 PBMC dose was detectable 
(Fig 27B).   
 
Figure 27: Comparison of signal produced by 20 million PBMC from two different 
donors. Two doses of 15x106 PBMC were prepared from different sources.  In the 
first, a high labeling efficiency (1.2x1011 19F/cell) was observed producing a strong 
signal in the ham shank (A).  The second source had a low labeling efficiency 
(4.2x1010 19F/cell), resulting in a low observed signal (B). 
5.4 Discussion 
To our knowledge, this is the first study conducted where a primary PBMC and 19F 
cellular MRI were used to track and quantify in vivo migration in a mouse model.  The 
high throughput of small animal models allows for rapid testing and optimization of 
treatment. Our data showed that pretreatment with either GM-CSF or IL-1b enhanced 
migration to the draining LN. It is likely that some PBMC migration occurred to all of the 
nodes; but in some cases the signal was insufficient to reach the detection threshold 
necessary for 19F-MRI.  This is particularly relevant to the untreated control group where 
signal was only detected in a single node.  Since treatment efficacy has been linked to the 
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number of PBMC which ultimately reach the nodes,11,12 improving migration efficiency 
and consistency is of the utmost importance to improving clinical outcomes.  
The translational potential of 19F-MRI was investigated with a clinical 3T MRI.  At 3T, 
Cell Sense has been shown to have a T1 of 423ms and a T2 of 155ms, producing an ideal 
bSSFP flip angle of 62°,13 which is in  agreement with our observed optimal angle of 70°.  
It is interesting to note that sensitivity improved with higher resolution images (data not 
shown), in agreement with observations made at high-field and discussed in Section 
2.2.2.  For development of the clinical protocol, a ham shank phantom was used as a 
mock human leg due to the tissue similarities. The largest factor governing successful 
detection of PBMC was found to be the number of 19F/cell. Mean intracellular loading of 
PBMC ranged from 1010 – 1011 between patients, representing an order of magnitude 
difference in cell detection threshold (107 vs 106 PBMC, respectively).  Similar 
differences in intracellular uptake were also observed by Dr. Ahrens et al. when labeling 
DC with 19F.7  While in the development stages of clinical 19F-MRI, it may be necessary 
to pre-screen patients on the basis of intracellular loading.  In comparison to other clinical 
19F studies, PBMC were observed to label on average an order of magnitude lower than 
DC (3.9x1012 19F/cell)7 and stromal vascular fraction cells (2.8±2x1012 19F/cell);8 which 
translates into a proportional decrease in signal.  Yet, despite this inherent disability, the 
minimum number of detectable cells was similar compared to previous studies (DC: 
~5x106, SVF: 2x106, PBMC: 4.5x106).  The clinical protocol and hardware presented in 
this work for imaging the ham shank represents a 10x improvement in sensitivity 
compared to previous studies (table 5).   
This improvement in detection sensitivity is largely due to the small size of the surface 
coil used, as well as the higher number of imaging averages. We presented a significant 
improvement in detection sensitivity by using a small 4.3cm x 4.3 cm compared to a 
much larger 25.4cm x 17.8cm surface coil. However, this came along with a significant 
decrease in imaging depth; limiting the application to surface injections and superficial 
targets. Total imaging time was contained within the self-imposed clinical limit of 
30minutes.  However, despite these improvements sensitivity still represents the largest 
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Table 5: Overview of clinical 19F cell tracking protocols published to date 
Cell Type 
Pulse Sequence & 
Imaging Time 
Year 
Reported Detection 
limit (19F spins) 
Dendritic Cell7 FLASH – 9.5min 2014 ~1.85x1019 
Stromal Vascular 
Fraction8 
bSSFP – 3.5min 2015 5.6x1018 
PBMC bSSFP – 15min 2016 3.8x1017 
limitation of clinical 19F-MRI.  This is due to the fundamental low sensitivity of the NMR 
signal, where net magnetization is only increased by 1 per 205 spins at 1.5T.  By 
comparison, the high sensitivity of iron-oxide based cellular MRI is due to the indirect 
detection of iron oxide through its influence on the highly abundant 1H signal. Although 
magnetization increases linearly with field strength, the drive for clinical translation 
limits this to 3T in most situations. Several techniques, such as hyperpolarization, have 
been used with great success in other x-nuclei to temporarily increase magnetization.  But 
the rapid loss of magnetization with time (order of seconds) makes this inapplicable with 
cell tracking.  This is further complicated by the fact that only 5% of injected cells are 
expected to migrate to the lymph node.  Based upon the sensitivity of this protocol, we 
can estimate that an initial subcutaneous injection of 90x106 PBMC would be required to 
detect migration of cells to a lymph node, assuming all PBMC migrated to a single node.  
Improvements in acquisition with different sequences, such as: ultrashort echo time 
(UTE)-SSFP,14 advanced array coil configurations,8,15 and post processing techniques, 
such as compressed sensing16 will be required to increase sensitivity to the necessary 
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levels.  For now, migration of PBMC must be approximated based upon the decrease in 
19F signal at the injection site over time. Finally, the minimum number of detectable cells 
can be improved by increasing the amount of 19F contained within a cell.  Unfortunately, 
this is currently limited by phenotypic changes and decreasing viability when cells are 
forced to internalize more agent.  The design of novel 19F agents will be necessary to 
safely enhance uptake. 
In this study, we present the highest sensitivity for 19F detection reported thus far in the 
literature with a clinical protocol. Moreover, this is the first investigation to show 
quantifiable signal of 19F labeled PBMC at a depth of 1.2cm using clinical 19F MRI 
hardware and protocol, as all other studies have only detected signal of surface injected 
cells.7,8 As outlined in Table 5, significant improvements in detection sensitivity have 
been made each year since the first clinical 19F cellular MRI study.  With the recent rapid 
expansion of the field, there is strong potential for development of the necessary 
technological advancements to help secure the role of 19F in the clinical cell therapy 
realm. 
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Chapter 6  
6 Summary and Future Work 
This work is the first implementation of 19F-MRI for cell tracking in Canada. Several 
advances to the field of cell tracking have been accomplished. First, Chapter 3 describes 
the first time the bSSFP pulse sequence was used to quantify 19F-labeled MSC in vivo. In 
Chapter 4 we demonstrate the first time dual 19F- and iron cellular MRI techniques were 
used for the simultaneous tracking of the fate of a stem cell transplant and the resulting 
cellular inflammatory response.  Finally, in Chapter 5 we show first results of imaging of 
19F-labeled PBMC on a GE 3T clinical MRI system using a clinical imaging protocol. 
Detection sensitivity was improved upon by an order of magnitude based on previously 
published protocols.  
6.1 Discussion and Conclusions 
19F-MRI is an emerging cell tracking technique, with excellent potential for clinical 
application.  This thesis has aimed to advance the development of 19F-MRI techniques 
and expand applications in both the pre-clinical and clinical realms.  Developing a non-
invasive, non-cytotoxic, and quantifiable cellular imaging technology opens numerous 
avenues of research in the fields of cellular therapy, inflammation, and cancer research. 
6.1.1 Chapter 2 & 3 – Development of Pre-clinical 19F-MRI and 
Tracking the Fate of Stem Cell Implants 
In Chapters 2&3, pre-clinical techniques were developed for imaging and quantifying 
MSC.  Imaging data was supported by histology and immunohistochemistry. We were 
the first to show accurate quantification with bSSFP and to describe techniques for 
avoiding isoflurane background signal.  The main findings were: 
1) bSSFP allows for accurate quantification of cell pellets and confirmation of 
administered cell dose on the day of transplant 
2) 19F-MRI can be used to identify differences in stem cell fate over time between 
transplant models.  In vivo quantification of the 19F-signal displayed clearance of the 
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mMSCs in the two weeks following administration in the isograft model.  In the 
immune-compromised xenograft, signal persisted over this same time period. 
3) When the natural immune system clearance is inhibited, such as in immune-
compromised mice, bystander labeling of macrophages can confuse longitudinal 
image interpretation. 
These findings demonstrate the versatility of 19F-MRI for tracking cells.  The techniques 
developed and lessons learned in this project directly influenced our imaging protocols in 
subsequent studies.  In particular, the improvements to quantification accuracy and 
avoiding isoflurane signal represent significant development milestones. Finally, the 
technique was applied to assess the differences in stem cell fate between transplant 
models.  Here we were able to longitudinally image changes in the number of stem cells 
remaining at the site of implantation.  However, assessing the infiltration of immune cells 
to the implant site still required the use of ex vivo immunohistochemistry; tracking this 
occurrence was the primary goal of the next study. 
6.1.2 Chapter 4 – Application of Dual 19F- and Iron-cellular MRI 
Agents to Track the Infiltration of Immune Cells to the Site of 
a Rejected Stem Cell Transplant 
In chapter 4, we built on our pre-clinical imaging by demonstrating that 19F-MRI can be 
combined with iron oxide cell tracking techniques to provide additional information on 
the rejection of stem cell transplants.  We were the first to combine stem cells labeled 
with 19F in vitro with intravenous labeling of phagocytic immune cells in situ. The main 
findings were: 
1) Following injection of IV SPIO, signal from the 19F labeled stem cells dropped 
significantly due to iron oxide induced signal quenching.  The 19F-signal did not 
change from this point until endpoint on day 14. 
2) The signal void region, indicating the presence of inflammatory cells, extended 
beyond the site of the stem cell transplant itself.  No signal void was observed in the 
opposite limb which had not received a stem cell transplant, or in mice which only 
received a saline sham injection. 
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3) Following in situ labeling of immune cells with 19F, no significant change in signal 
was observed over the 14 days.  This suggests there is no change in the number of 
immune cells present at the transplant site following the initial influx. 
These findings implement a new method for combining cellular MRI techniques to obtain 
additional in vivo information. The significant decrease in both 19F and 1H signal 
resulting from the influx of SPIO labeled immune cells provides a method to track 
rejection and could be used as an early indicator of graft failure, without having to wait 
for symptomatic analysis.  Overall, this study highlights the exciting potential of 
combining cellular MRI techniques to advance pre-clinical research. 
6.1.3 Chapter 5 – Development of a Clinical Protocol for Imaging 
19F-labeled PBMC 
In Chapter 5, we focused on translating our knowledge of 19F-MRI from the high-field, 
pre-clinical 9.4T MRI to a clinical 3T system.  In this study, we report the first time a 19F 
clinical cell tracking protocol has been developed for a General Electric MRI system. 
This is the first report of imaging the heterogeneous PBMC mixture with 19F-MRI. In 
addition, we present the best detection sensitivity for a clinical protocol currently 
reported in the literature and the first time cells were detected at greater than 1cm depth 
in a clinical phantom. The main findings were: 
1) PBMC could be imaged following administration into a ham shank with a dual-tuned 
surface coil and 30minute clinical protocol.  Total imaging time for this protocol was 
kept under 30minutes for patient comfort; including patient positioning, localizers, 
anatomical 1H, and 19F scans. 
2) A detection limit of 3.8x1017 19F atoms was measured, representing approximately 
4.5x106 PBMC.  This is an order of magnitude higher sensitivity than previous 
studies had reported.  In addition, cells could be detected following a surface 
intradermal injection, and at 1cm depth with a subcutaneous injection. 
3) Intracellular uptake of the 19F agent was highly variable between patients, 
representing more than an order of magnitude of difference in minimum number of 
detectable cells. Based upon these results, in the development stage of clinical 19F-
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MRI, it may be necessary to pre-screen patients on a basis of intracellular loading 
prior to study enrollment. 
These findings highlight the potential for clinical application of 19F-MRI cell tracking.  
The minimum detection limit of 4.5x106 PBMC is well above clinical doses applied with 
sipuleucel-T therapy.  In addition, by using a very small surface coil and sacrificing 
imaging depth we were able to improve detection sensitivity by an order of magnitude,1 
and by more than two orders over the first study published in 2014.2  Overall this work 
lays the foundation necessary for approval of a 19F clinical trial at Robarts Research 
Institute.  
6.2 Limitations 
Loss of Intracellular Label 
Cellular 19F-MRI of pre-labeled cells is limited by the inability to longitudinally 
determine the number of live cells, when and if bystander labeling has occurred, and the 
low sensitivity.  From just the images, it is impossible to determine what percentage of 
signal is produced by viable, 19F-labeled therapeutic cells. Correlating 19F-signal with that 
produced by bioluminescence imaging (BLI) could be used to address this limitation.  
BLI detects ATP producing cells, expressing the luciferase gene. Signal is theoretically 
quantitative, but severely attenuated with tissue depth.  For discerning bystander labeling, 
a more successful approach may lie in the combination of cellular MRI techniques, as 
shown by Dr. Hitchens and discussed in chapter 4.3 It is interesting to note that in certain 
circumstances 19F-MRI provides some advantage over SPIO when considering bystander 
labeling.  Due to the lower sensitivity, significantly more bystander labeling is necessary 
at a given site before false-positive signal is detected.4  But due to this decreased 
sensitivity the detection of therapeutic 19F-labeled cells can be missed if they do not reach 
the detection threshold.  This is of concern with partial volume effects where a low 
number of cells is separated further by different voxels.  
In vivo Quantification 
A large number of assumptions are made when quantifying 19F-labeled cells in vivo.  
Prior to cell administration, we assume the re-suspended cells are homogeneously 
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distributed.  If the cells are not perfectly homogenous, this influences the number of cells 
injected, and more importantly, the number of cells set aside for NMR.  Since 
quantification is reliant on the accuracy of the intracellular 19F uptake measurement, this 
is a significant potential source of error.  In the images, regions of interest are selected by 
the user by eye and quantification is performed on hand-drawn ROIs.  Determination of 
the boundary outlining noise from signal is often not concrete, and different ROI’s may 
be drawn by users of differing experience.  Finally, quantification assumes the signal at 
the ROI is comparable to the signal at the reference tube to determine the number of 19F 
atoms present.  This is influenced by the different relaxation rates due to environment 
from the agar reference tube and the in vivo, intracellular agent.  In addition, any changes 
in B1 field homogeneity would introduce additional quantification error as 19F atoms 
experience different flip angles. Based upon our observations, we would approximate the 
error from bSSFP 19F quantification on any individual scan to be +/- 15%.  With repeated 
imaging, this value has been found to converge to the expected quantification number.   
Quantification of 19F signal is further hindered in the presence of iron oxide, and at only 
“apparent” cell number can be measured due to the drastic differences in relaxation.  
With the bSSFP sequence, SPIO quenches both 1H and 19F.  The degree of quenching is 
difficult to determine due to the complexity of the sequence.  Dr. Hitchens has shown that 
application of a UTE sequence can be used to generate a 19F image even in the presence 
of iron oxide.3  However, it is not clear how the accuracy of quantification would be 
affected in this case.   
Clinical Protocol Optimization 
Finally, the clinical protocol was optimized in a cadaverous ham shank.  Although similar 
in appearance to a human thigh in 1H images, there are distinct differences between the 
physiology of the two.  First, the skin of the ham is significantly thicker and tougher than 
that of a human.  This may assist in holding the injected cells in a tighter pellet following 
interdermal injection.  The lack of functioning immune system and active blood supply 
would also hinder the movement and clearance of PBMC.  In a clinical case, it may be 
expected that PBMC have higher potential to disperse and migrate away from the site in 
the time between injection and imaging.   
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6.3 Future Work 
Future work will focus on applying the imaging techniques developed within this thesis 
to pre-clinical models of disease and to the first 19F-cell tracking clinical trial in Canada. 
6.3.1 Application of 19F-MRI to Pre-clinical Disease Models 
This thesis focused on developing a 19F-site and techniques for application in a variety of 
disease models.  One such model is in correlating the presence and number of tumour 
associated macrophages (TAMs) with tumourgenicity.  TAMs have been shown to 
promote metastasis and immune tolerance.5 Building on the techniques introduced in this 
thesis, Ashley Makela (PhD Candidate) from Dr. Foster’s lab has shown 19F-MRI 
provides superior information over SPIO for visualizing TAMs in vivo. The 19F-agent is 
administered intravenously and labels phagocytic macrophages in situ. Information such 
as the relative number of TAMs and spatial distribution throughout the tumour can be 
compared with this technique.  
Investigating the factors involved with the migration of labeled APCs is also a promising 
direction for 19F-MRI.  Future work could explore the application of antigen-loaded APC 
on a tumour bearing animal.  When combined with 19F-MRI, the therapeutic effects could 
be correlated with the number of 19F-labeled APCs which arrive at the draining LN.  
Anti-cancer treatment effects could be further optimized by adjusting the route of 
delivery, dosage, APC cell-type, and pre-labeling strategies.  The PBMC work is being 
led by Corby Fink (PhD Candidate) and the DC work by Michael Smith (MSc Candidate) 
in Dr. Dekaban’s lab. 
6.3.2 Two-colour 19F-MRI for Imaging Transplant Rejection 
In chapter 4, the largest limitation introduced by application of iron and 19F cellular MRI 
was the inability to quantify either the stem cell transplant or the resulting inflammation 
due to the negative iron contast.  However, by using two spectrally different 19F-agents, 
inflammation signal could be differentiated from stem cell signal. This would provide a 
significant advantage over the current technique since it would allow both processes to be 
quantified over time.  An addition advantage could be found from the combination of two 
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19F agents and a SPIO agent, which would allow for three distinct cell populations to be 
tracked simultaneously.  In combination with the new imaging technology, Magnetic 
Particle Imaging (MPI), all three of these cell populations can be spatial located and 
quantified.6 
6.3.3 Phase-I Clinical Trial Investigating Safety and Tolerability of 
19F-labeled Human PBMC 
With the establishment of a sufficiently sensitive clinical protocol, the next step is to run 
a Phase I clinical trial will focus on the safety and tolerability of 19F-labeled PBMC.  The 
trial (ClinicalTrials.gov identifier: NCT02921373) is set to enroll 6 healthy and 6 prostate 
cancer volunteers. Autologous PBMC will be collected, separated, and labeled with 19F 
under Good Manufacturing Practice (GMP) conditions necessary for human 
administration.  Secondary outcomes of the trial will be to further optimize detection of 
the injection site, and determine if LN signal can be observed in any volunteers.  The trial 
will be overseen by Health Canada and Western University Ethics committee.   
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